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ABSTRACT: Demonstrating intracellular protein target engagement is an essential step in the 
development and progression of new chemical probes and potential small molecule therapeutics. 
However, this can be particularly challenging for poorly studied and non-catalytic proteins, as 
robust proximal biomarkers are rarely known. To confirm that our recently discovered chemical 
probe 1 (CCT251236) binds the putative transcription factor regulator pirin in living cells, we 
developed a heterobifunctional protein degradation probe. Focusing on linker design and 
physicochemical properties, we generated a highly active probe 16 (CCT367766) in only three 
iterations, validating our efficient strategy for degradation probe design against non-validated 
protein targets. 
INTRODUCTION 
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Drug discovery is reliant on recombinant proteins and biochemical screens to develop structure 
activity relationships (SAR) and progress compounds.1 However, the conditions in biochemical 
assays often display little relevance to the intracellular environment, which can result in a failure 
to translate high target affinity to activity within a living cell.2 Target-proximal biomarker 
modulation is the most important confirmation of intracellular target engagement.3 
Unfortunately, this is often not possible in early stage chemical probe or drug discovery projects, 
especially against novel biological targets, where poorly understood biology and pharmacology 
make it difficult to discover and robustly validate biomarkers; a process that is particularly 
challenging for non-catalytic proteins. 
Owing to the importance of confirming intracellular target engagement, several techniques 
have been developed. The over-expression of fusion proteins allows for a direct readout of target 
occupancy.4 However, the engineered cell lines are often difficult to generate and the protein 
label can impact compound binding. The cellular thermal shift assay (CETSA) is a label-free 
technique for intracellular target engagement.5 It exploits compound-induced stabilization of 
protein melting temperatures, but CETSA cannot be applied to all targets.6 Activity-based protein 
profiling (ABPP) methods utilize non-selective irreversible covalent ligands, or intracellular 
fluorescence polarization probes, combined with intracellular reversible ligand competition, to 
study target engagement.7 Proteolysis targeting chimeras (PROTACs)8,15 and specific and non-
genetic IAP-dependent protein erasers (SNIPERs)9 are heterobifunctional molecules that induce 
rapid and selective protein degradation, via the proteasome, within living cells. One portion of 
the molecule engages the target protein while the other, attached via a flexible linker, recruits an 
E3 ligase to ubiquitinate the target, marking it for degradation as part of the cullin-RING finger 
machinery.10,15 
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We recently reported the development of a high affinity pirin chemical probe 1 (CCT251236, 
SPR KD = 44 nM) discovered through a cell-based phenotypic screen for inhibitors of the heat 
shock transcription factor 1 (HSF1) stress pathway.11 Pirin is an iron-binding member of the 
cupin super family of proteins and has been reported as a putative transcription factor 
regulator12,13 It has no known enzymatic function in mammalian cells, no endogenous ligands 
have been reported and no validated proximal biomarkers have been described.14 This makes 
demonstrating intracellular target engagement in living cells very challenging.  
We hypothesized that we could demonstrate chemical probe 1 binding to pirin within living 
cells by developing a pirin-targeting Protein Degradation Probe (PDP). 
RESULTS AND DISCUSSION 
Protein Degradation Probe Design. PDPs have been described against various proteins,15 with 
the bromodomain epigenetic target, BRD4, the most extensively studied.16 These 
heterobifunctional PDP molecules have utilized several ligands that bind to the E3 ligases: 
VHL,17 the IAP proteins,18 and CRBN.19 Despite the rapid expansion in PDP research, there 
remains no clear methodology to determine which proteins are amenable to PDP-mediated 
degradation,20 which E3 ligase ligand should be exploited or the optimal features of probe design. 
The structure of the linker, its length and physicochemical properties, have all been demonstrated 
to be important for PDP activity.21 The linker controls the formation of the essential ternary 
complex,22 with evidence that it may stabilize the protein-protein interaction (PPI) between the 
target and the E3 ligase, rather than forming a detached linear ternary complex (figure 1), 
although it is unclear whether the ternary complex is part of the multi-protein cullin-RING finger 
complex.23,24,25 
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Figure 1. (Top) Pirin (5JCT)/CRBN (5CI1)/PDP ternary complex design model. The PDP can 
either stabilize a PPI or simply bring the proteins in close proximity, depending on the role of the 
linker. (Bottom Left) Cartoon representation of the chemical probe 1 (yellow) bound to 
recombinant pirin (5JCT). The cloud represents the shape of the binding pocket with key 
residues shown in black and the metal in orange. Red=oxygen, blue=nitrogen. Hydrogens and 
solvent are omitted for clarity except the water coordinated to the metal, shown as a red sphere. 
Both representations were generated using the PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC. (Bottom Right) Key residues in the binding site and the clear solvent exposed 
vector for the chemical probe 1 binding to pirin are shown, adapted from an analysis using MOE 
2014.09. The ethyl pyrrolidine solubilizing group of chemical probe 1 was not resolved in the 
crystal structure and therefore is not drawn in the analysis. 
Although we had discovered a high affinity ligand for pirin, there was no evidence that this 
protein would be a suitable substrate for ubiquitination by a PDP-recruited E3 ligase, without 
which, extensive linker optimization could be futile. Therefore, we initially designed a 
synthetically tractable 15-atom linker that we predicted would not affect the affinity of the PDP 
for the isolated target proteins.26 Analysis of the crystal structure of the chemical probe 1 bound 
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to pirin (figure 1, PDB: 5JCT)11 suggested that the solvent-exposed solubilizing group vector 
should be amenable to linker attachment. We selected a CRBN-targeting thalidomide ligand as 
the basis of our E3 ligase binding motif, due to its low molecular weight. The CRBN-targeting 
ligand would be attached via the solvent exposed hydroxyl group of the 4-hydroxythalidomide 
analogue 2.27 The linker would then attach the pirin- and CRBN-targeting specific binding groups 
via two amide moieties, to give our first generation pirin-targeting PDP 3 (scheme 1). 
Scheme 1. Design and Synthesis of the First Generation PDP 3 based on the Chemical 
Probe 1 
 
Reagents and conditions: (a) i) PPh3, 
tButyl 2-hydroxyacetate, DTBAD, THF, 0 ºC→RT, 16 h, 
75%; ii) HCO2H, DCM, 40 ºC, 16 h, 54%; iii) HATU, DIPEA, DMF, 
tButyl (2-(2-
aminoethoxy)ethyl)carbamate, RT, 16 h, 81%; iv) 4 M HCl in dioxane, 0.5 h, 100%; (b) i) ethyl 
4-bromobutanoate, K2CO3, DMF, RT, 16 h, 37%; (c) Herrmann’s palladacycle,
29 tBu3PHBF4, 
MoCO6, DBU, 2-(trimethylsilyl)ethan-1-ol, 130 
oC, 62% (d) i) TBAF, THF, RT, 16 h; (e) i) 
HATU, DIPEA, DMF, RT, 38% (over 2 steps); ii) LiOH.H2O, MeOH/THF/H2O, RT, 48 h, 18% 
(f) HATU, DIPEA, DMF, 74%. For the synthesis of hydroxythalidomide 2 see reference 28. 
The CRBN-targeting motif 4 of PDP 3 was synthesized from 4-hydroxythalidomide 2 in 2 
steps and 84% yield, in a similar manner to that previously described.28 The pirin-binding motif 
of the PDP 3 was synthesized from 6-bromoquinoline 5, via a palladium-mediated carbonylation 
reaction on the ether derivative 6. Trapping the carbonylation intermediate with 2-
(trimethylsilyl)ethan-1-ol gave the silylethyl-protected ester 7,29 which facilitated TBAF-
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selective hydrolysis. Amide coupling to the previously described bis-aniline derivative 8,11 was 
followed by hydrolysis of the aliphatic linker ester to give acid 9. Final amide coupling to the 
CRBN-targeting derivative 4 gave the first generation pirin-targeting PDP 3 in 10 steps and 0.4% 
overall yield. 
The First Generation PDP. Analysis of the heterobifunctional PDP 3 revealed that it possessed 
good affinity for recombinant pirin (table 1, entry 1) when measured using SPR, confirming the 
success of the rationally designed attachment vector.30 The affinity of PDP 3 was then assessed 
against the CRBN-DDB1 complex, with DDB1 acting as a scaffolding protein, using an FP-
assay similar to that previously described (figure S6).31 PDP 3 displayed moderate affinity for 
CRBN-DDB1, with Ki=230 nM,32 comparable to the affinities of the parent CRBN ligands, 
thalidomide and lenalidomide (figure S7). 
Following confirmation that both binding motifs of the PDP 3 retained high affinity for their 
respective targets, we then investigated its activity against pirin in human cancer cell lines. 
Several cell lines were assessed for CRBN expression by quantitative capillary electrophoresis 
(figure S17).33 The SK-OV-3 ovarian carcinoma cell line34 displayed good basal CRBN and also 
pirin expression and there was no observable depletion of pirin in these cells when treated with 
chemical probe 1 (1 µM, data not shown), so this line was selected for further study. 
Unfortunately, treatment of SK-OV-3 cells with PDP 3, at high concentrations (>1 µM) and for 
extended time periods (>48 h), resulted in no measurable effects on the cancer cells (data not 
shown). 
The Second Generation PDP. We speculated several causes for the failure of the first 
generation PDP 3. Pirin may simply be incompatible with this methodology, and if so, no further 
improvements could be made.35 Alternatively, CRBN could be the wrong E3 ligase target to 
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deplete pirin36 or the linker length could be inconsistent with formation of the ternary complex.26 
Finally, the physicochemical properties of PDP 3 could be limiting its intracellular free 
concentration.37 Given these variables, designing a PDP against a protein target that has not 
previously been validated as being susceptible to E3 ligase-directed degradation is challenging, 
as optimization cycles can appear lengthy and the difficult and low yielding synthesis 
discourages the generation of multiple analogues. It was also unclear how strict and narrow the 
requirements for optimal PDP design would be. We hypothesized that the physicochemical 
properties of the PDP were the primary cause of the failure of the first generation probe, so 
began a redesign process that should increase cell membrane flux, whilst maintaining the same 
linker length and CRBN-targeting ligand (Table 1). By carrying out multiple changes to the PDP, 
we aimed to minimize the number of iterative design cycles, so we could more rapidly validate 
this approach. 
Table 1. Physicochemical Properties and Affinities for Recombinant Protein Targets of the 
Three Generations of PDPs 
 
Entry Compd X R Linker HBDa ALogPb LogD7.4
c 
tPSA 
(Å2)d 
KS 
(µM)e 
Pirin  
SPR/KD 
(pKD±SEM)
f 
CRBN/DDB1 
FP/IC50 
(pIC50±SEM)
g 
CRBN/Ki 
(nM)h 
1 3 Me 
  
5 2.8 2.2 258 1 
110 nM 
(6.97±0.02) 
850 nM 
(6.07±0.14) 
220 
2 10 F 
  
4 2.0 1.9 244 5 
230 nM 
(6.63±0.01) 
410 nM 
(6.38±0.07) 
95 
3 16 Cl 
  
3 3.9 2.7 207 2 
55 nM 
(7.26±0.04) 
490 nM 
(6.31±0.10) 
120 
4 21 Cl 
  
3 3.9 2.9 207 2 
>1300 nM 
(<5.90) 
420 nM 
(6.38±0.10) 
98 
SF=significant figure. All data was reprocessed using GraphPad Prism 7.01. See figures S8-
S16. SEM=standard error of the mean. aHBD=hydrogen bond donor count. bALogP was 
calculated using Biovia Pipeline Pilot Version 9.5, 2 SF. cLogD7.4 measured using a HPLC-based 
method, n=1, 2 SF. dtPSA was calculated using ChemDraw (16.0.1.4) based on the O- and N-
count, 3 SF. eKS=kinetic solubility in pH7.4 phosphate buffer at room temperature, n=1, 1 SF. 
f
KD values are reported to 2 SF and are calculated by equilibrium analysis using a one site 
O
N
H
O
O
N
H
O
O
O
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specific binding model from SPR sensorgrams at equilibrium where possible, pKD=-log (KD (M) 
x 10-9) and represents the geometric mean of n=3 independent biological repeats. gIC50 values are 
reported to 2 SF and are calculated from an FP-assay dose-response curve to displace a 
thalidomide derived fluorescent probe using a log[Inhibitor] vs. response – Variable slope (four 
parameters) model, pIC50=-log (IC50 (M) x 10
-9) and represents the geometric mean of n=3 
independent biological repeats, also see reference 31. hKi values are calculated from the 
geometric mean CRBN-DDB1 complex IC50 and the FP-probe KD using methods described in 
reference 32. 
The design of heterobifunctional molecules unavoidably results in high molecular weight 
compounds, making it difficult to balance their physicochemical properties in a manner 
consistent with acceptable permeability and solubility.38 In the case of the first generation pirin-
targeting PDP 3, although the LogD7.4 was acceptable (table 1, entry 1),39 the linker had 
introduced two new hydrogen bond donors (HBD), which can have a negative impact on 
permeability. The calculated tPSA was very high (258 Å2), although it is inevitable that tPSA 
will be high for large molecules and outside the standard cut-offs for cell permeability, unless the 
compounds are highly lipophilic.40 In design a second generation PDP, we followed standard 
medicinal chemistry principles to reduce the tPSA and HBD count, whilst maintaining an 
acceptable LogD7.4. To achieve this, we redesigned the ether linker in the first generation PDP 3 
to include a methylene piperazine that would project into solvent, based on analysis of the crystal 
structure of the chemical probe 1 bound to pirin. The resulting tertiary amide would remove one 
HBD. We also sought to mask the quinoline amide HBD, using a dipole-dipole interaction, via a 
bioisosteric replacement with fluorine.41 These changes resulted in the design of the second 
generation pirin-targeting PDP 10 (scheme 2) with a modestly reduced tPSA (244 Å2). 
Scheme 2. Synthesis of Second (10) and Third (16) Generation Probes and Control 
Compounds 
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Reagents and conditions: (a) i) X=F 12, 2-methylquinoline carboxylic acid, oxalyl chloride, 
DMF, DCM; RT, 3 h; then pyridine, 18 h Quant; ii) Fe(0), NH4Cl, EtOH/H2O, 90 ºC, 1 h, Quant; 
(b) 2,3-dihydrobenzo-[b][1,4]-dioxine-6-carboxylic acid, oxalyl chloride, DMF, DCM, RT, 3 h; 
then pyridine RT, 2 h, 85%; (c) i) SeO2, 1,4-dioxane/DMF, reflux, 1 h; ii) N-Boc-piperazine, 
DCM, RT, 12 h then NaBH(OAc)3, DCM, RT, 2 h, 94% (over 2 steps); iii) TFA, DCM, RT, 2 h, 
69% (d) i) 2, PPh3, 
tButyl 2-hydroxyacetate, DTBAD, THF, 0 ºC→RT, 16 h, 75%; ii) HCO2H, 
DCM, 40 ºC, 16 h, 54%; iii) HATU, DIPEA, DMF, tButyl 3-(2-aminoethoxy)propanoate, RT, 16 
h, 72%; iv) HCO2H, DCM, 40 ºC, 6 h, 93% (e) HATU, DIPEA, DMF, RT, 16 h, 52%; (f) i) 
X=Cl 17, 2-methylquinoline carboxylic acid, oxalyl chloride, DMF, DCM, RT, 3 h; then 
pyridine 2 h, 88%; ii) Fe(0), NH4Cl, EtOH/H2O, 90 ºC, 1 h, Quant; (g) i) 2,3-dihydrobenzo-
[b][1,4]-dioxine-6-carboxylic acid, oxalyl chloride, DMF, DCM, RT, 3 h; then pyridine 2 h, 
61%; (h) i) SeO2, DMF, 1,4-dioxane, 50 ºC, 16 h; ii) N-Boc-piperazine, NaBH3CN, AcOH, 
DMF, 0 ºC→RT, 16 h iii) 4M HCl in dioxane, MeOH 0 ºC→RT, 16 h, 32% over 3 steps; (i) 2-
[2-(2-hydroxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate, K2CO3, DMF, RT, 16 h, 48%; j) 
PPh3, DTBAD, THF, RT, 2 h, 27%; (k) i) 23, 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid, 
oxalyl chloride, DMF, DCM, RT, 2 h; then pyridine 48 h, 84%; ii) Pd/C, EtOH/DCM, H2 (1 
atm), 77%; iii) 2-methylquinoline carboxylic acid, oxalyl chloride, DMF, DCM; RT, 2 h; then 
pyridine 16 h, 58%; then same procedure as from 18, 6% yield over 5 steps. (l) SeO2, 1,4-
dioxane/DMF, 50 ºC, 5.5 h; ii) N-ethylpiperazine, DCM, RT, 20 h; then NaBH(OAc)3, DCM, 
RT, 2 h, 35% (over 2 steps). 
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The synthesis of PDP 10 began from the fluoroaniline carboxamide 11, synthesized in a 
similar manner to that previously described from 2-fluoro-5-nitroaniline 12 in 3 steps and 85% 
yield. Amide coupling to give bisamide 13 and benzylic oxidation using selenium dioxide,42 was 
followed by reductive amination of the resulting aldehyde with N-Boc-piperazine, and 
subsequent deprotection, to give 14. The CRBN-targeting thalidomide derivative precursor 15 
was prepared in 4 steps and 27% yield from 4-hydroxythalidomide 2. Final amide coupling with 
monosubstituted piperazine 14 gave the second generation pirin-targeting PDP 10 in 11 steps and 
8% overall yield (scheme 2). 
PDP 10 displayed a similar affinity for recombinant pirin and CRBN-DDB1 to our first 
generation probe 3 (table 1, entry 2), so was progressed to cellular assessment of pirin 
degradation. Pleasingly, treatment of SK-OV-3 ovarian cancer cells with 10 at 3.0 µM total 
concentration for up to 48 h revealed a clear and time-dependent depletion of intracellular pirin 
expression (figure S18).43 This confirmed, for the first time, that pirin is amenable to modulation 
using a PDP and that the bisamide chemotype not only binds recombinant pirin with high 
affinity, but also binds pirin within living cells.  
Although demonstrating pirin depletion with the second generation probe 10 was a very 
encouraging result, we found the effects were poorly reproducible. The concentrations of PDP 10 
needed to observe pirin degradation were high and close to its kinetic solubility (KS). 
Furthermore, at least 24 h of compound exposure was needed before pirin degradation was 
observed (figure S18). To explore the cause of the variable results obtained with PDP 10, we 
assessed its chemical stability. At room temperature, PDP 10 was stable as a solid and in DMSO 
stock solution (>1 month, data not shown), but at 37 oC in pH7.4 phosphate buffer, consistent 
with the cell assay conditions, it underwent rapid decomposition (table S1), displaying a half-life 
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of only ~4 h. This poor chemical stability was consistent with the known decomposition of the 
parent CRBN-targeting thalidomide ligand under these conditions, where multiple hydrolysis 
products of the imide and glutaramide moieties are observed.44 The chemical probe 1 displayed 
no instability under these conditions; therefore, we concluded that the facile hydrolysis of the 
CRBN-targeting motif limited the reproducibility of our slow-acting second generation pirin-
targeting PDP 10. 
The Third Generation PDP. In the design of a third generation probe, we aimed to increase 
permeability further. This should result in higher intracellular free concentrations more quickly, 
mitigating the poor stability of the CRBN-targeting motif. We decided to carry out a bioisosteric 
replacement of the central ring fluorine for the larger and more sterically hindering chlorine 
substituent.45 However, we were concerned that the increase in lipophilicity from this exchange 
would negatively impact both the solubility and permeability of the probe. Large lipophilic 
heterobifunctional molecules are particularly susceptible to aggregation,46 and this decreases the 
free concentration that drives cell membrane flux.47 To balance the lipophilicity, we removed the 
tertiary amide bond to the piperazine, introducing a cationic amine, which would be substantially 
charged at pH 7.4 (Moka Version 2.5.2, pKa=8.0).48 The second amide in the linker was also 
removed, reducing the HBD count further and increasing the overall flexibility of the ligand, 
consistent with the formation of the crucial PDP ternary protein complex. The linker length was 
reduced by one atom to accommodate these changes and resulted in the design of the third 
generation pirin-targeting PDP 16 (CCT367766), which now displayed a notably reduced, but 
still high, tPSA (207 Å2). 
The synthesis of the pirin-targeting motif of the third generation PDP 16 was carried out in a 
similar manner to that previously described starting from 2-chloro-5-nitroaniline 17, to give 
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chlorobisamide 18 in 3 steps and 54% yield (scheme 2). Oxidation of the methylquinoline 
moiety with SeO2, reductive amination of the resulting aldehyde with N-Boc-piperazine and N-
Boc deprotection gave 19 in 32% yield. Following SN2 alkylation with the ether linker to give 
20, selective Mitsunobu alkylation with 4-hydroxythalidomide 2 gave the third generation PDP 
16 in 8 steps and 2% overall yield. A non-pirin-binding negative control matched pair 
compound, PDP 21, based on our negative control pirin chemical probe,11 was synthesized from 
regioisomer 23 in a similar manner in 2% overall yield. A non-CRBN binding control 22,49 was 
also synthesized from 18, utilizing reductive amination with N-ethylpiperazine, in 35% yield 
(scheme 2). 
 
Figure 2. (A) Representative SPR sensorgram of the third generation PDP 16 and recombinant 
pirin. (B) Representative binding curve of PDP 16 in the CRBN-DDB1 FP-assay. 
Analysis of the third generation PDP 16 confirmed that it retained acceptable lipophilicity 
(table 1, entry 3), but also displayed a 4.2-fold increase in affinity for recombinant pirin 
compared to the second generation PDP 10 (figure 2A) and comparable affinity for CRBN 
(figure 2B). SK-OV-3 cells were then treated with PDP 16 at concentrations from 50 to 1500 nM 
for up to 24 h (figure 3).  
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Figure 3. A: Immunoblot of SK-OV-3 human ovarian cancer cells demonstrating the depletion 
of pirin protein using the third generation PDP 16 and the time-dependent hook-effect. B: 
Immunoblot demonstrating the concentration-dependent depletion of pirin protein after 2 h 
exposure in SK-OV-3 cells. C: Capillary electrophoresis and immunoassay were used to quantify 
the pirin protein expression after 2 h exposure with PDP 16, all values are normalized to vinculin 
loading control and relative to the measured basal pirin protein expression, all bars represent the 
arithmetic mean of n=3 independent biological repeats, error bars are SEM. D: Proteomics 
analysis of the third generation PDP 16 (50 nM) exposure (4 h) in SK-OV-3 cells compared to 
vehicle control, using a tandem mass tagging (TMT) MS2 protocol on the cell lysate, 8547 
quantifiable proteins were identified, each blue dot represents a single quantifiable protein, pirin 
is marked in red (adjusted p value=1.4 x 10-4), p values were calculated using a linear modelling 
based t-test and corrected for multiple comparisons using the Benjamini-Hochberg method to 
give the p(adj) values shown, dotted lines represent 2-fold depletion of the protein and a 
p(adj)=0.05. 
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In contrast to our earlier generation PDPs, near complete pirin degradation was now observed 
with just 50 nM treatment and only 2 h exposure (figure 3A). Increasing the total initial 
concentration of pirin-targeting PDP 16 resulted in a clear hook-effect. This bell-shaped 
concentration-response is consistent with the formation of a ternary complex.22 Interestingly the 
hook-effect was seen to decrease over time (24 h), possibly either due to the slower degradation 
at high concentration or from the depletion of PDP 16 due to thalidomide hydrolysis (half-
life=~3 h, figure S1), which would reduce the effective free concentration below the negative 
cooperativity threshold of the ternary complex.22 Pirin degradation was subsequently shown to be 
concentration-responsive with activity at concentrations as low as 0.5 nM (figure 3B), which was 
confirmed with a quantitative capillary electrophoreses-based immunoassay (figure 3C). The 
negative control benzodioxane regioisomer PDP 21, (table 1, entry 4) displayed no pirin 
depletion at equimolar concentrations (figure S19),50 and degradation was also confirmed to be 
proteasome-dependent by rescue following pre-incubation with the proteosome inhibitor, 
MG132 (500 nM, figure S19).51 We then carried out whole proteome mass spectrometry, to 
estimate the cellular selectivity of the pirin-targeting PDP 16 in an unbiased manner, quantified 
using tandem mass tagging (TMT) (figure 3D, www.proteomics.com). After treating SK-OV-3 
cells with 50 nM PDP 16 for 4 h, and comparing to vehicle treated cells using Benjamini-
Hochberg corrected p values, we found that from 8547 quantifiable proteins identified, only pirin 
(2.3-fold reduction, p(adj)=1.4 x 10-4) displayed a statistically significant (p(adj)<0.05)52 
difference in protein expression. 
To confirm that our chemical probe 1 also bound pirin within SK-OV-3 cancer cells, we 
carried out competition experiments, designed to rescue pirin depletion by PDP 16. The 
concentrations required for a mutually exclusive binding ligand to displace a probe molecule, are 
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dependent on the affinity of the ligand relative to the ratio of the free concentration of the probe 
and its affinity for the protein target complex.53 Because the depletion of pirin is a non-
equilibrium event that does not necessarily require complete target occupancy, it is more difficult 
to observe competition at later time points owing to continued protein turnover.54 Pretreating SK-
OV-3 cells with 10 µM thalidomide, as a CRBN-binding competitive ligand, demonstrated that 
after 2 h treatment with PDP 16 (5 nM) we successfully rescued pirin depletion (figure S19). The 
non-CRBN-binding control chlorobisamide 22, displayed high affinity for recombinant pirin 
(SPR, KD=21 nM, pKD=7.68±0.03, n=3). Pretreatment of SK-OV-3 cells with chlorobisamide 22 
displayed concentration-dependent rescue of pirin expression, following treatment with the PDP 
16 (figure 4, top), with complete rescue observed at 1 µM. Finally, pre-treatment with the 
chemical probe 1 demonstrated clear rescue of pirin depletion, confirming intracellular target 
engagement (figure 4, bottom). 
 
Figure 4. Intracellular competition studies with PDP 16 and the chemical probes. SK-OV-3 cells 
were pre-treated with increasing concentrations of chemical probe for 4 h before exposing to 
Page 15 of 68
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 16
PDP 16 for 2 h at the concentrations shown. Cells were then lysed and protein expression 
analyzed using immunoblot. For clarity, gel images have been cropped where appropriate. 
CONCLUSION 
Exploiting cell-based phenotypic screens to identify new disease-associated therapeutic targets 
is an increasingly frequent strategy in drug discovery. While this approach can identify novel 
targets with unique mechanisms of action, these proteins are often poorly characterized and can 
lack identifiable enzymatic activity, ligands and biomarkers of target engagement. The main 
focus of research into PDPs has been as potential therapeutics with novel mechanisms of action. 
We designed a PDP as an intracellular probe against the poorly-understood and non-catalytic 
molecular target, pirin. Developing PDPs to confirm intracellular target engagement, and 
potentially develop intracellular SAR, against challenging proteins, is an important addition to 
the current methods for compound profiling.  
For PDPs to be used as target engagement probes, their rapid development and validation is 
crucial. The ideal strategies for efficient and successful PDP design are still under investigation 
and will clearly improve as more protein targets are modulated and additional crystallographic 
evidence of the target protein/E3 ligase/PDP ternary complexes are discovered. The number of 
variables involved in PDP design against non-validated target proteins can make the process 
daunting. By focusing on the physicochemical properties of our probe molecules, in only three 
iterations, we developed a selective degradation probe that eliminates pirin at low concentration 
and in a short time-period. This confirmed our chemical probe 1 does bind pirin in an 
intracellular environment and PDP 16 provides another chemical tool to study a largely 
unexplored protein. 
EXPERIMENTAL SECTION 
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General Experimental.  
Unless otherwise stated, reactions were conducted in oven dried glassware under an 
atmosphere of nitrogen or argon using anhydrous solvents. All commercially obtained reagents 
and solvents were used as received. Thin layer chromatography (TLC) was performed on pre-
coated aluminum sheets of silica (60 F254 nm, Merck) and visualized using short-wave UV 
light. Flash column chromatography was carried out on Merck silica gel 60 (partial size 40-65 
µm). Column chromatography was also performed on a Biotage SP1 or Biotage Isolera Four 
purification system using Biotage Flash silica cartridges (SNAP KP-Sil) or for reverse phase 
purifications SNAP Ultra C18 cartridges. Ion exchange chromatography was performed using 
acidic Isolute Flash SCX-II columns. Semi-preparative HPLC was performed on an Agilent 6120 
system, flow 20 mL/min, eluents 0.1% acetic acid in water and 0.1% acetic acid in methanol, 
gradient of 10% to 100% organic phase. Lipophilic method: Chromatographic separation at room 
temperature was carried out using a 1200 Series Preparative HPLC (Agilent, Santa Clara, USA) 
over a 15 minute gradient elution (Grad15min,20mls) from 60:40 to 0:100 water:methanol (both 
modified with 0.1% formic acid) at a flow rate of 20 mL/min. 1H-NMR spectra were recorded on 
Bruker AMX500 (500 MHz) spectrometers using an internal deuterium lock. Chemical shifts are 
quoted in parts per million (ppm) using the following internal references: CDCl3 (δH 7.26), 
MeOD (δH 3.31) and DMSO-d6 (δH 2.50). Signal multiplicities are recorded as singlet (s), 
doublet (d), triplet (t), quartet (q) and multiplet (m), doublet of doublets (dd), doublet of doublet 
of doublets (ddd), broad (br) or obscured (obs). Coupling constants, J, are measured to the 
nearest 0.1 Hz. 13C-NMR spectra were recorded on Bruker AMX500 spectrometers at 126 MHz 
using an internal deuterium lock. Chemical shifts are quoted to 0.01 ppm, unless greater 
accuracy was required, using the following internal references: CDCl3 (δC 77.0), MeOD (δC 
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49.0) and DMSO-d6 (δC 39.5). High resolution mass spectra were recorded on an Agilent 1200 
series HPLC and diode array detector coupled to a 6210 time of flight mass spectrometer with 
dual multimode APCI/ESI source or on a Waters Acquity UPLC and diode array detector 
coupled to a Waters G2 QToF mass spectrometer fitted with a multimode ESI/APCI source. All 
compounds were >95% purity by LCMS analysis unless otherwise stated. 
Thalidomide (http://www.sigmaaldrich.com/catalog/product/sigma/t144?lang=en&region=GB, 
Accessed August 29, 2017), Lenalidomide 
(http://www.sigmaaldrich.com/catalog/product/aldrich/cds022536?lang=en&region=GB, 
Accessed August 29, 2017) and MG132 
(http://www.sigmaaldrich.com/catalog/product/sigma/m8699?lang=en&region=GB, Accessed 
August 29, 2017) were purchased from Sigma Aldrich and used without further purification. 
The pirin chemical probe 1 CCT251236 was synthesized using the previously described 
procedure.11 
2-(2,6-Dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione 2 
3-Aminopiperidine-2,6-dione hydrochloride (300 mg, 1.82 mmol) was added to a solution of 
4-hydroxyisobenzofuran-1,3-dione (299 mg, 1.82 mmol) and triethylamine (0.38 mL, 2.73 
mmol) in anhydrous THF (36.5 mL) and the reaction heated to reflux for 24 h under inert 
atmosphere. The reaction mixture was allowed to cool to room temperature, then 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (384 mg, 2.00 mmol) and DMAP (22 mg, 0.18 mmol) were 
added. The reaction was heated to reflux for 24 h. Then, the reaction mixture was allowed to cool 
and the solvents were removed under reduced pressure. The resulting residue was taken up in 
methanol and passed sequentially through two ion exchange columns (Isolute SCX-II), eluting 
with methanol to afford the title compound as an amorphous off-white solid (422 mg, 84%). 1H 
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NMR (500 MHz, DMSO-d6) δ 11.18 (s, 1H), 11.09 (s, 1H), 7.65 (dd, J = 8.4, 7.2 Hz, 1H), 7.32 
(dd, J = 7.1, 0.7 Hz, 1H), 7.25 (dd, J = 8.4, 0.7 Hz, 1H), 5.07 (dd, J = 12.8, 5.5 Hz, 1H), 2.88 
(ddd, J = 17.0, 13.9, 5.5 Hz, 1H), 2.64 – 2.46 (m, 2H), 2.02 (dtd, J = 13.0, 5.3, 2.2 Hz, 1H). 
LCMS (ESI+) RT = 0.77 min, 100%, M+H+ 275, M+Na+ 297.28 This compound is also 
commercially available from several suppliers. 
 
tert-Butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate 
Triphenylphosphine (0.261 g, 0.996 mmol) and tert-butyl 2-hydroxyacetate (101 mg, 0.77 
mmol) were dissolved in anhydrous THF (3 mL), while stirring at 0 ºC. Then, a solution of 
DTBAD (229 mg, 0.10 mmol) in anhydrous THF (2 mL), was added dropwise. Finally, a 
solution of (2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione) 2 in anhydrous THF (3 
mL) was added. The mixture was stirred for 1 h at 0 ºC, then allowed to warm to room 
temperature and stirred overnight. Then, the solvent was removed under reduced pressure. The 
crude product was purified by Biotage chromatography using a gradient of 0 to 50% EtOAc in 
cyclohexane, to afford the title compound as an amorphous white solid (224 mg, 0.577 mmol, 75 
% yield). 1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 7.80 (dd, J = 8.5, 7.3 Hz, 1H), 7.48 (d, 
J = 7.2 Hz, 1H), 7.38 (d, J = 8.5 Hz, 1H), 5.10 (dd, J = 12.8, 5.5 Hz, 1H), 4.97 (s, 2H), 2.89 (ddd, 
J = 17.0, 13.9, 5.4 Hz, 1H), 2.64 – 2.52 (m, 2H), 2.07 – 2.00 (m, 1H), 1.43 (s, 9H). 13C NMR 
(126 MHz, DMSO-d6) δ 172.78, 169.89, 167.14, 166.71, 165.12, 155.03, 136.76, 133.25, 119.96, 
116.44, 115.90, 81.92, 65.50, 48.80, 30.95, 27.68, 21.97. HRMS (ESI+): calcd for C15H13N2O7 
(M + H, - tBu)+ 333.0717, found 333.0722. 
 
2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid  
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tert-Butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate (1.30 g, 3.35 
mmol) was dissolved in anhydrous DCM, then formic acid (12.8 mL, 335 mmol), was added 
while stirring at room temperature. The reaction was stirred overnight at 40 ºC. The solvents 
were removed under reduced pressure and the resulting residue purified by reverse phase Biotage 
chromatography using a gradient of 0% to 50% MeOH in water + 0.1% formic acid, to afford the 
title compound as an amorphous white solid (600 mg, 1.81 mmol, 54% yield). 1H NMR (500 
MHz, DMSO-d6) δ 13.29 (s, 1H), 11.11 (s, 1H), 7.79 (dd, J = 8.5, 7.3 Hz, 1H), 7.47 (d, J = 7.2 
Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 5.10 (dd, J = 12.8, 5.4 Hz, 1H), 4.98 (s, 2H), 2.89 (ddd, J = 
16.9, 13.9, 5.4 Hz, 1H), 2.64 – 2.52 (m, 2H), 2.04 (dtd, J = 13.0, 5.4, 2.3 Hz, 1H). LCMS (ESI+): 
RT = 0.71 min, 100%, M+Na+ 355.28 
 
tert-Butyl 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)propanoate  
2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (217 mg, 0.65 
mmol), tert-butyl 3-(2-aminoethoxy)propanoate (124 mg, 0.65 mmol) and DIPEA (0.34 mL, 
1.96 mmol) were dissolved in anhydrous DMF (3.27 mL) at room temperature under inert 
atmosphere. HATU (230 mg, 0.98 mmol) was added and the reaction stirred overnight. The 
solvents were removed under reduced pressure and the resulting residue was purified by reverse 
phase Biotage chromatography using a gradient of 10-90% MeOH in water + 0.1% formic acid 
to afford the title compound as an amorphous white solid (236 mg, 72%). 1H NMR (500 MHz, 
MeOD) δ 7.82 (dd, J = 8.4, 7.4 Hz, 1H), 7.55 (dd, J = 7.3, 0.5 Hz, 1H), 7.46 – 7.43 (m, 1H), 5.16 
(dd, J = 12.6, 5.5 Hz, 1H), 4.78 (s, 2H), 3.71 (t, J = 6.2 Hz, 2H), 3.62 – 3.56 (m, 2H), 3.52 – 3.48 
(m, 2H), 2.90 (ddd, J = 18.0, 14.4, 5.2 Hz, 1H), 2.82 – 2.70 (m, 2H), 2.50 (td, J = 6.2, 3.8 Hz, 
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2H), 2.16 (dddd, J = 10.8, 7.9, 5.1, 2.4 Hz, 1H), 1.42 (s, 9H). 13C NMR (126 MHz, MeOD) δ 
174.55, 172.81, 171.33, 170.00, 168.31, 167.59, 156.21, 138.16, 134.96, 121.60, 119.30, 117.89, 
81.75, 70.01, 69.26, 67.75, 50.56, 40.15, 37.22, 32.20, 28.34, 23.66. HRMS (ESI+): calcd for 
C24H30N3O9 (M + H)
+ 504.1982, found 504.1981. 
 
tert-Butyl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)ethyl)carbamate  
2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (0.19 g, 0.56 mmol), 
tert-butyl (2-(2-aminoethoxy)ethyl)carbamate (0.11 g, 0.56 mmol) and DIPEA (0.29 ml, 1.68 
mmol) were dissolved in anhydrous DMF (2.80 mL) under inert atmosphere at room 
temperature. HATU (198 mg, 0.84 mmol) was added and the reaction stirred for 16 h. The 
reaction mixture was concentrated in vacuo and the resulting residue purified by Biotage 
chromatography using a gradient of 0-2% methanol in ethyl acetate.  However, this material was 
not pure, therefore the material was purified by further Biotage chromatography using a gradient 
of 1-10% EtOH in DCM to afford the title compound as an amorphous white solid (243 mg, 
81%). 1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.02 (t, J = 5.4 Hz, 1H), 7.81 (dd, J = 8.5, 
7.3 Hz, 1H), 7.49 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.76 (t, J = 4.7 Hz, 1H), 5.12 (dd, 
J = 12.8, 5.4 Hz, 1H), 4.79 (s, 2H), 3.44 (t, J = 5.6 Hz, 2H), 3.38 (t, J = 6.1 Hz, 2H), 3.31 (d, J = 
5.5 Hz, 2H), 3.08 (q, J = 5.6 Hz, 2H), 2.89 (ddd, J = 16.6, 13.8, 5.3 Hz, 1H), 2.65 – 2.51 (m, 
2H), 2.08 – 1.98 (m, 1H), 1.36 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 172.73, 169.85, 
166.88, 166.80, 166.72, 165.45, 155.59, 155.00, 136.92, 133.03, 120.34, 116.75, 116.02, 77.63, 
69.02, 68.55, 67.48, 48.80, 38.38, 30.95, 28.22, 21.99. HRMS (ESI+): calcd for C24H30N4O9Na 
(M + Na)+ 541.1911, found 541.1915. 
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N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(4-((2-(2-(2-((2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethyl)amino)-4-
oxobutoxy)quinoline-6-carboxamide 3 
N-(2-(2-Aminoethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamide hydrochloride 4 (21.0 mg, 0.046 mmol), 4-((6-((5-(2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-
yl)oxy)butanoic acid (25.0 mg, 0.046 mmol) and DIPEA (0.032 mL, 0.184 mmol) were 
dissolved in anhydrous DMF (0.23 mL) under inert atmosphere. HATU (16.0 mg, 0.069 mmol) 
was added and the reaction left to stir at room temperature for 2 h. The reaction was concentrated 
in vacuo, then purified by reverse phase Biotage chromatography using a gradient of 20-100% 
MeOH in water + 0.1% formic acid to afford the title compound as a beige solid (32 mg, 74%). 
1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1H), 10.07 (s, 1H), 10.06 (s, 1H), 8.56 (d, J = 1.9 Hz, 
1H), 8.37 (d, J = 8.8 Hz, 1H), 8.21 (dd, J = 8.8, 2.1 Hz, 1H), 8.01 (t, J = 5.5 Hz, 1H), 7.91 (t, J = 
5.5 Hz, 1H), 7.87 – 7.83 (m, 2H), 7.80 (dd, J = 8.5, 7.3 Hz, 1H), 7.58 (dd, J = 8.3, 2.1 Hz, 1H), 
7.54 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.4, 2.2 Hz, 1H), 7.48 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 8.5 
Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 5.12 (dd, J = 
12.8, 5.4 Hz, 1H), 4.79 (s, 2H), 4.42 (t, J = 6.5 Hz, 2H), 4.33 – 4.26 (m, 4H), 3.45 (t, J = 5.7 Hz, 
2H), 3.42 (t, J = 5.9 Hz, 2H), 3.36 – 3.28 (m, J = 5.5 Hz, 2H – obscured by water peak), 3.24 (q, 
J = 5.8 Hz, 2H), 2.89 (ddd, J = 16.3, 13.6, 5.1 Hz, 1H), 2.64 – 2.52 (m, 2H), 2.29 (t, J = 7.3 Hz, 
2H), 2.23 (s, 3H), 2.11 – 1.93 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δ 172.74, 171.66, 
169.87, 166.90, 166.71, 165.44, 164.91, 164.34, 162.79, 154.96, 147.58, 146.33, 142.92, 140.16, 
137.28, 136.90, 136.33, 133.01, 130.10, 130.00, 128.75, 128.37, 128.10, 127.68, 126.72, 123.99, 
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121.19, 120.32, 118.61, 118.11, 116.83, 116.74, 116.65, 116.02, 113.94, 68.91, 68.58, 67.48, 
65.38, 64.39, 64.02, 48.80, 38.44, 38.33, 31.78, 30.94, 24.62, 21.99, 17.48. HRMS: calcd for 
C49H48N7O13 (M+H)
+, 942.3305; found 942.3322. 
 
N-(2-(2-Aminoethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamide 4 
tert-Butyl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)ethyl)carbamate (24 mg, 0.05 mmol) was stirred in 4 M HCl in 
dioxane (1.16 mL, 4.63 mmol) at room temperature. After 30 min, the solution was concentrated 
and used as the hydrochloride salt without further purification. LCMS (ESI+): RT = 0.63 min, 
100%, M+H+ 419. 
 
Ethyl 4-((6-bromoquinolin-2-yl)oxy)butanoate 6 
6-Bromoquinolin-2(1H)-one 5 (200 mg, 0.89 mmol) was dissolved in anhydrous DMF (4.5 
mL) at room temperature under nitrogen and potassium carbonate (185 mg, 1.34 mmol) was 
added. The reaction mixture was allowed to stir for 1.5 h, then ethyl 4-bromobutanoate (0.26 mL, 
1.79 mmol) was added dropwise and the reaction stirred overnight. The reaction mixture was 
poured into water (50 ml) and the aqueous layer extracted with DCM (3 x 15 ml). The combined 
organic layer was dried (Na2SO4) and concentrated in vacuo to afford the crude product as an 
orange oil. This material was purified by Biotage chromatography using a gradient of 0-100% 
EtOAc in cyclohexane to afford the required O-linked isomer as a white solid (111 mg, 37%) 
and the undesired N-linked isomer as a yellow oil (164 mg, 55%). The regioisomers were 
distinguishable by NOE spectroscopy. 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 8.9 Hz, 1H), 
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7.88 – 7.87 (br m, 1H), 7.71– 7.69 (m, 2H), 6.92 (d, J = 8.8 Hz, 1H), 4.52 (t, J = 6.3 Hz, 2H), 
4.18 (q, J = 7.1 Hz, 2H), 2.55 (t, J = 7.5 Hz, 2H), 2.19 (ddd, J = 13.7, 7.4, 6.3 Hz, 2H), 1.28 (t, J 
= 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.39, 162.35, 145.41, 137.80, 132.82, 129.61, 
129.11, 126.42, 117.29, 114.30, 65.17, 60.59, 31.27, 24.60, 14.39. HRMS (ESI+): calcd for 
C15H17
79BrNO3 (M+H)
+, 339.0419; found 339.0403. 
 
2-(Trimethylsilyl)ethyl 2-(4-ethoxy-4-oxobutoxy)quinoline-6-carboxylate 7 
Ethyl 4-((6-bromoquinolin-2-yl)oxy)butanoate 6 (554 mg, 1.64 mmol), tri-tert-
butylphosphonium tetrafluoroborate (95 mg, 0.33 mmol) and Herrmann’s palladacyle (77 mg, 
0.08 mmol) were added to a microwave vial and suspended in 2-(trimethylsilyl)ethanol (15 ml). 
Molybdenum hexacarbonyl (865 mg, 3.28 mmol) followed by DBU 1.0 M in THF (4.91 mL, 
4.91 mmol) were then added and the vial promptly sealed. The reaction was heated to 130 °C for 
1 h in a microwave. The reaction mixture was diluted with DCM and filtered to remove solids. 
The filtrate was concentrated in vacuo. This residue was diluted with water (20 ml) and extracted 
with DCM (3 x 20 ml). The combined organic layer was washed with brine and concentrated 
under reduced pressure. The resulting crude was purified by Biotage chromatography using a 
gradient of 0-100% EtOAc in cyclohexane to give 472 mg product (88% purity by LCMS, 62%), 
as a brown oil. 1H NMR (500 MHz, CDCl3) δ 8.47 (d, J = 1.9 Hz, 1H), 8.23 (dd, J = 8.7, 1.9 Hz, 
1H), 8.06 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 4.56 (t, J = 6.3 
Hz, 2H), 4.51 – 4.43 (m, 2H), 4.17 (q, J = 7.1 Hz, 2H), 2.55 (t, J = 7.4 Hz, 2H), 2.19 (p, J = 7.0, 
6.5 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.23 – 1.15 (m, 2H), 0.12 (s, 9H). LCMS (ESI+): RT =1.79 
min, 88%, (M+H)+ 404. 
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Ethyl 4-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-
methylphenyl)carbamoyl)quinolin-2-yl)oxy)butanoate. 
To a stirring solution of 2-(trimethylsilyl)ethyl 2-(4-ethoxy-4-oxobutoxy)quinoline-6-
carboxylate 7 (463 mg, 1.15 mmol) in anhydrous THF (12 mL) at room temperature under 
nitrogen was dropwise added TBAF 1.0 M in THF (1.72 mL, 1.72 mmol). The reaction was 
allowed to stir at RT overnight, after which time the starting material had been consumed as 
indicated by LCMS. The reaction mixture was diluted with water and concentrated in vacuo to 
remove the THF. The aqueous layer was acidified to ~pH 2 with 1M HCl aq. and extracted with 
DCM (3 x 15 ml). The combined organic layer was washed with brine (20 mL) and dried 
(Na2SO4) to afford the crude product as a yellow oil. This material was used directly in the next 
step without further purification. LCMS (ESI+): RT = 1.57 min, 84%, (M+H)+ 304.  
2-(4-Ethoxy-4-oxobutoxy)quinoline-6-carboxylic acid (74 mg, 0.24 mmol) was dissolved in 
anhydrous DMF (2 ml) and DIPEA (0.12 ml, 0.67 mmol) was added, followed by HATU (105 
mg, 0.28 mmol). The reaction was allowed to stir for 5 min and then N-(3-amino-4-
methylphenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide (63 mg, 0.22 mmol) was added. 
The reaction was stirred at room temperature overnight. The reaction mixture was poured into 
water and the resulting precipitate collected by filtration. The precipitate was dissolved in 
DCM/MeOH and pre-absorbed onto silica. The crude material was purified by Biotage 
chromatography using a gradient of 0-5% MeOH in DCM and then by preparative HPLC (20 
mls, lipophilic method) to afford the title compound as an amorphous beige solid (48 mg, 38% 
over two steps). 1H NMR (500 MHz, CDCl3) δ 8.30 (d, J = 1.9 Hz, 1H), 8.13 – 8.05 (m, 3H), 
7.93 – 7.87 (m, 3H),7.68 (dd, J = 8.3, 2.1 Hz, 1H), 7.44 (d, J = 2.1 Hz, 1H), 7.38 (dd, J = 8.4, 2.2 
Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 4.57 (t, J = 
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6.3 Hz, 2H), 4.31 (ddd, J = 11.1, 3.7, 1.8 Hz, 4H), 4.18 (q, J = 7.1 Hz, 2H), 2.56 (t, J = 7.4 Hz, 
2H), 2.35 (s, 3H), 2.21 (p, J = 6.7 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 173.37, 165.49, 165.09, 163.48, 148.69, 146.89, 143.67, 139.54, 136.92, 136.11, 131.17, 
130.22, 128.23, 128.05, 127.62, 127.30, 125.17, 124.61, 120.59, 117.63, 117.52, 116.89, 114.86, 
114.58, 65.40, 64.71, 64.34, 60.62, 31.26, 24.58, 17.52, 14.39. HRMS (ESI+) : calcd for 
C32H32N3O7 (M+H)
+, 570.2253; found 570.2222. 
 
4-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-
methylphenyl)carbamoyl)quinolin-2-yl)oxy)butanoic acid 9. 
To a stirring solution of ethyl 4-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-
methylphenyl)carbamoyl)quinolin-2-yl)oxy)butanoate (37 mg, 0.065 mmol) in THF (0.5 mL) 
and MeOH (0.25 mL) was added a solution of LiOH.H2O (13.6 mg, 0.325 mmol) in water (0.25 
mL). After 2 days the reaction mixture was diluted with water (30 ml) and the aqueous layer 
acidified to ~pH 2 with 1M HCl aq. The aqueous layer was extracted with DCM (3 x 15 ml). The 
combined organic layer was washed with 1M HCl aq. (20 ml), brine (20 ml) and dried (Na2SO4), 
then concentrated in vacuo to afford the product as an amorphous pale yellow solid (6.5 mg, 
18%). This material was used directly in the next reaction without further purification. 1H NMR 
(500 MHz, DMSO-d6) δ 12.16 (br s, 1H), 10.07 (s, 2H), 8.56 (d, J = 1.9 Hz, 1H), 8.38 (d, J = 8.8 
Hz, 1H), 8.22 (dd, J = 8.7, 2.1 Hz, 1H), 7.89 – 7.83 (m, 2H), 7.58 (dd, J = 8.3, 2.1 Hz, 1H), 7.54 
(d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.4, 2.2 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 7.11 (d, J = 8.8 Hz, 
1H), 6.99 (s, 1H), 4.47 (t, J = 6.5 Hz, 2H), 4.34 – 4.21 (m, 4H), 2.43 (t, J = 7.4 Hz, 2H), 2.24 (s, 
3H), 2.03 (p, J = 7.0 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 174.11, 164.94, 164.35, 162.78, 
147.57, 146.34, 142.93, 140.23, 137.29, 136.33, 130.11, 130.05, 128.76, 128.40, 128.12, 127.68, 
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126.75, 124.03, 121.20, 118.61, 118.11, 116.84, 116.66, 113.94, 65.06, 64.39, 64.02, 30.30, 
24.05, 17.49. HRMS (ESI+): calcd for C30H28N3O7 (M+H)
+, 542.1922; found 542.1905. 
 
N-(2-Fluoro-5-nitrophenyl)-2-methylquinoline-6-carboxamide  
Oxalyl chloride (3.25 mL, 38.4 mmol) was added dropwise to a solution of 2-methylquinoline-
6-carboxylic acid (6.59 g, 35.2 mmol) and DMF (0.0062 mL, 0.080 mmol) in anhydrous DCM 
(80 mL). The reaction mixture was stirred at room temperature for 3 h and then concentrated 
under reduced pressure. The residue was dissolved in DCM (30 mL) and concentrated again 
under reduced pressure. The resulting dry residue was dissolved in pyridine (80 mL) and 2-
fluoro-5-nitroaniline 12 (5.00 g, 32.0 mmol) was added in one portion. The reaction mixture was 
stirred at room temperature for 18 h and then poured onto water (100 mL). The green precipitate 
was filtered and washed with water (3 x 20 mL), diethyl ether (3 x 20 mL) and DCM (10 mL), to 
afford the title compound as a light green solid, which was carried onto the next step without 
further purification (10.4 g, Quant.). 1H NMR (500 MHz, DMSO-d6) δ 10.71 (s, 1H), 8.72 (dd, J 
= 6.5, 2.9 Hz, 1H), 8.63 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 8.5 Hz, 1H), 8.23 (dd, J = 8.8, 2.0 Hz, 
1H), 8.21 – 8.16 (m, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.65 (app t, J = 9.5 Hz, 1H), 7.55 (d, J = 8.4 
Hz, 1H), 2.71 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.53, 161.22, 158.67 (d, J = 258.2 
Hz), 148.65, 143.72, 137.32, 130.36, 128.88, 128.48, 128.00, 127.08 (d, J = 13.9 Hz), 125.33, 
123.18, 122.14 (d, J = 9.6 Hz), 121.25 (d, J = 3.8 Hz), 117.19 (d, J = 22.8 Hz), 25.07. 19F NMR 
(470 MHz, DMSO-d6) δ -110.20. HRMS (ESI
+): calcd for C17H13FN3O3 (M + H)
+, 326.0935; 
found 326.0931. 
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N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-(3-(2-(2-((2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)propanoyl)piperazin-
1-yl)methyl)quinoline-6-carboxamide 10 
3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)propanoic acid 15 (15 mg, 0.033 mmol), N N-(5-(2,3-
Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(piperazin-1-
ylmethyl)quinoline-6-carboxamide 14 (18 mg, 0.033 mmol) and HATU (19 mg, 0.050 mmol) 
were dissolved in anhydrous DMF (0.34 ml) at room temperature under inert atmosphere. 
DIPEA (23.4 µL, 0.134 mmol) was added and the reaction stirred for 16 h. The reaction mixture 
was concentrated in vacuo and purified by reverse phase Biotage chromatography (10-80% 
MeOH in water + 0.1% formic acid), however the material obtained was not pure. Further 
purification by Biotage chromatography using a gradient of 2-50% EtOH in DCM afforded the 
product as an off-white amorphous solid (17 mg, 52%). 1H NMR (500 MHz, DMSO-d6) δ 11.12 
(s, 1H), 10.39 (s, 1H), 10.18 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.50 (d, J = 8.4 Hz, 1H), 8.25 (dd, 
J = 8.8, 2.0 Hz, 1H), 8.14 (dd, J = 7.1, 2.6 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.99 (t, J = 5.6 Hz, 
1H), 7.80 (dd, J = 8.5, 7.3 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.65 (ddd, J = 9.0, 4.4, 2.7 Hz, 1H), 
7.56 – 7.46 (m, 3H), 7.39 (d, J = 8.5 Hz, 1H), 7.30 (dd, J = 10.1, 9.0 Hz, 1H), 6.99 (d, J = 8.4 
Hz, 1H), 5.12 (dd, J = 12.8, 5.4 Hz, 1H), 4.79 (s, 2H), 4.31 (td, J = 5.3, 3.6 Hz, 4H), 3.82 (s, 2H), 
3.62 (t, J = 6.6 Hz, 2H), 3.52 – 3.41 (m, 6H), 3.33 (s, 2H), 2.89 (ddd, J = 16.7, 13.7, 5.4 Hz, 1H), 
2.62 – 2.52 (m, 4H), 2.43 (d, J = 21.7 Hz, 4H), 2.09 – 1.99 (m, 1H). 13C NMR (126 MHz,CDCl3) 
δ 171.71, 169.89, 168.79, 167.12, 166.76, 166.06, 165.15, 165.08, 161.23, 154.62, 149.43 (d, J = 
240.9 Hz), 149.10, 146.95, 143.59, 137.71, 137.06, 134.97, 133.71, 131.94, 129.99, 127.99, 
127.94 (d, J = 9.5 Hz), 127.28, 126.81, 126.42 (d, J = 11.2 Hz), 122.32, 120.74, 119.68, 118.21, 
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117.48, 117.46 (d, J = 6.5 Hz), 117.05 (d, J = 7.0 Hz), 116.93, 115.30 (d, J = 20.0 Hz), 113.74, 
69.20, 68.22, 67.52, 64.74, 64.70, 64.32, 53.39, 53.15, 49.42, 45.80, 41.68, 39.47, 33.60, 31.52, 
23.00. HRMS (ESI+): calcd for C50H48FN8O12 (M + H)
+, 971.3370; found 971.3343. 
 
N-(5-Amino-2-fluorophenyl)-2-methylquinoline-6-carboxamide 11 
To a solution of N-(2-fluoro-5-nitrophenyl)-2-methylquinoline-6-carboxamide (10.4 g, 32.0 
mmol) in ethanol (120 mL) and water (40 mL), ammonium chloride (12.0 g, 224 mmol) and iron 
powder (12.5 g, 224 mmol) were added in one portion and the resulting suspension was allowed 
to stir at 90 °C for 1 h. The reaction mixture was allowed to cool to room temperature, diluted 
with MeOH (20 mL) and DCM (20 mL) and filtered through a pad of Celite. The resulting 
filtrate was concentrated under vacuum to afford a light brown solid which was re-dissolved in a 
mixture of DCM:MeOH (9:1, 150 mL) and washed with saturated aqueous NaHCO3 (150 mL). 
The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to 
afford a yellow solid as crude product, which was taken directly onto the next step without 
further purification (9.46 g, Quant.). 1H NMR (500 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.57 (d, J = 
1.8 Hz, 1H), 8.39 (d, J = 8.5 Hz, 1H), 8.19 (dd, J = 8.8, 2.0 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 
7.52 (d, J = 8.4 Hz, 1H), 6.94 (dd, J = 10.3, 8.8 Hz, 1H), 6.89 (dd, J = 6.6, 2.7 Hz, 1H), 6.46 – 
6.39 (m, 1H), 5.05 (br s, 2H), 2.70 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 164.93, 160.84, 
148.49, 147.72 (d, J = 233.9 Hz), 145.08 (d, J = 1.9 Hz), 137.19, 131.19, 128.44, 128.33, 127.95, 
125.50 (d, J = 13.1 Hz), 125.34, 122.99, 115.54 (d, J = 20.6 Hz), 111.52, 111.39 (d, J = 6.6 Hz), 
25.05. 19F NMR (470 MHz, DMSO-d6) δ -138.12. HRMS (ESI
+): calcd for C17H15FN3O (M + 
H)+, 296.1194; found 296.1191. 
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N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-methylquinoline-6-
carboxamide 13 
To a suspension of 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (12.7 g, 70.5 mmol) in 
anhydrous DCM (100 mL), a catalytic amount of anhydrous DMF (6.16 µl, 0.080 mmol) and 
oxalyl chloride (6.51 mL, 77.0 mmol) were added dropwise and the resulting green solution was 
allowed to stir at room temperature for 3 h. After which time, the reaction mixture was 
concentrated in vacuo to afford a dry pale green solid. The solid was dissolved in pyridine (100 
mL) and N-(5-amino-2-fluorophenyl)-2-methylquinoline-6-carboxamide (9.46 g, 32.0 mmol) 
was added in one portion. The resulting dark yellow suspension was allowed to stir for 2 h and 
was then poured onto water (100 mL). The yellow precipitate was filtered and washed with water 
(3 x 20 mL), diethyl ether (3 x 20 mL) and DCM (10 mL), to afford the crude product as a pale 
yellow solid, which was taken directly onto the next step without purification (12.5 g, 85%). 1H 
NMR (500 MHz, DMSO-d6): δ 10.38 (s, 1H), 10.19 (s, 1H), 8.62 (d, J = 1.7 Hz, 1H), 8.41 (d, J 
= 8.8 Hz, 1H), 8.23 (dd, J = 8.8, 1.9 Hz, 1H), 8.13 (dd, J = 7.0, 2.5 Hz, 1H), 8.03 (d, J = 8.8 Hz, 
1H), 7.68 – 7.62 (m, 1H), 7.57 – 7.46 (m, 3H), 7.29 (app t, J = 9.5, 1H), 6.99 (d, J = 8.4 Hz, 1H), 
4.34 – 4.28 (m, 4H), 2.71 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.09, 164.48, 160.95, 
151.83 (d, J = 243.4 Hz), 148.57, 146.45, 142.95, 137.22, 135.42 (d, J = 2.0 Hz), 130.87, 128.50, 
128.41, 127.94, 127.47, 125.39 (d, J = 9.5 Hz), 125.35, 123.05, 121.25, 118.81, 118.75 (d, J = 
13.0 Hz), 116.89, 116.69, 115.56 (d, J = 21.2 Hz), 64.41, 64.03, 25.06. 19F NMR (470 MHz, 
DMSO-d6) δ -126.65. HRMS (ESI+): calcd for C26H21FN3O4 (M + H)
+, 458.1511; found 
458.1499. 
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N-(5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-(piperazin-1-
ylmethyl)quinoline-6-carboxamide 14 
A solution of N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-
methylquinoline-6-carboxamide 13 (5.00 g, 10.9 mmol) and selenium dioxide (1.33 g, 12.0 
mmol) in anhydrous DMF (40 mL) and 1,4-dioxane (120 mL) was heated at reflux for 1 h. Then, 
the reaction mixture was allowed to cool to room temperature, diluted with DCM (20 mL) and 
filtered through a pad of Celite. The filtrate was concentrated under vacuum (using a 
heptane/EtOAc azeotrope to remove DMF) to afford the crude product as a yellow solid, which 
was carried onto the next step without further purification (5.15 g). 
A solution of N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-
formylquinoline-6-carboxamide (255 mg, 0.541 mmol) and tert-butyl piperazine-1-carboxylate 
(302 mg, 1.62 mmol) in anhydrous DCM (5 mL) was allowed to stir at 20 °C for 12 h, after 
which time, sodium triacetoxyborohydride (344 mg, 1.62 mmol) was added in one portion and 
the resulting mixture was allowed to stir at 20 °C for 2 h. The reaction was quenched with 
NaHCO3 saturated aqueous solution (5 mL) and extracted with a DCM:MeOH, 9:1 mixture (3 x 
5 mL). The crude product (pale yellow solid) was purified by column chromatography on silica 
gel using a gradient of 0-6% MeOH in DCM, followed by trituration in diethyl ether to afford the 
desired product as a pale beige solid (325 mg, 94%).  
To a suspension of tert-butyl 4-((6-((5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-
fluorophenyl)carbamoyl)quinolin-2-yl)methyl)piperazine-1-carboxylate (300 mg, 0.468 mmol) 
in anhydrous DCM (5 mL,), TFA (0.179 mL, 2.33 mmol) was added dropwise and the resulting 
mixture was allowed to stir at 20 °C for 3 h. The reaction mixture was concentrated under 
reduced pressure to afford the crude product as a light brown oil. The crude was purified by 
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column chromatography on silica gel using a gradient of 0-15% MeOH in DCM, followed by 
trituration in diethyl ether to afford the title compound as a white solid (174 mg, 69%). 1H-NMR 
(500 MHz, DMSO-d6): δ 10.42 (s, 1H), 10.20 (s, 1H), 8.73 (br s, 1H), 8.67 (d, J = 1.66 Hz, 1H), 
8.52 (d, J = 8.71 Hz, 1H), 8.27 (dd, J = 8.71, 1.66 Hz, 1H), 8.15 (dd, J = 7.08, 2.72 Hz, 1H), 8.09 
(d, J = 8.71 Hz, 1H), 7.74 (d, J = 8.42 Hz, 1H), 7.66 – 7.61 (m, 1H), 7.54 (d, J = 2.11 Hz, 1H), 
7.52 (dd, J = 8.42, 2.11 Hz, 1H), 7.30 (app t, J = 10.10 Hz, 1H), 6.99 (d, J = 8.42 Hz, 1H), 4.35 – 
4.27 (m, 4H), 3.90 (s, 2H), 3.19 – 3.09 (m, 4H), 2.76 – 2.66 (m, 4H). 13C NMR (126 MHz, 
DMSO-d6) δ 164.98, 164.50, 160.59, 151.87 (d, J = 243.8 Hz), 148.27, 146.47, 142.96, 137.76, 
135.45 (d, J = 2.7 Hz), 131.45, 128.79, 128.57, 128.13, 127.46, 126.25, 125.30 (d, J = 13.2 Hz), 
121.95, 121.26, 118.86, 118.78 (d, J = 7.8 Hz), 116.90, 116.70, 115.59 (d, J = 20.9 Hz), 64.42, 
64.04, 63.67, 49.45, 43.03. HRMS (ESI+): calcd for C30H29FN5O4 (M + H)
+, 542.2198; found 
542.2190. 
 
3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)propanoic acid 15 
tert-Butyl 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)propanoate (29 mg, 0.06 mmol) and formic acid (0.22 ml, 5.76 mmol) 
were dissolved in anhydrous DCM (0.29 mL) at 40 ºC for 6 h. The reaction mixture was 
concentrated in vacuo and the resulting residue purified by reverse phase Biotage 
chromatography using a gradient of 10-80% MeOH in water + 0.1% formic acid to afford the 
title compound as an amorphous white solid (24 mg, 93%). 1H NMR (500 MHz, DMSO-d6) δ 
12.21 (br s, 1H), 11.12 (s, 1H), 8.01 (t, J = 5.6 Hz, 1H), 7.81 (dd, J = 8.5, 7.3 Hz, 1H), 7.50 (d, J 
= 7.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 5.11 (dd, J = 12.9, 5.4 Hz, 1H), 4.79 (s, 2H), 3.60 (t, J = 
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6.4 Hz, 2H), 3.44 (t, J = 5.7 Hz, 2H), 3.30 (q, J = 5.8 Hz, 2H – partially obscured by water peak), 
2.94 – 2.82 (m, 1H), 2.64 – 2.51 (m, 2H), 2.48 – 2.41 (m, 2H), 2.08 – 1.99 (m, 1H). 13C NMR 
(126 MHz, DMSO-d6) δ 172.80, 172.69, 169.91, 166.92, 166.77, 165.48, 155.00, 136.98, 133.06, 
120.36, 116.78, 116.07, 68.58, 67.49, 66.06, 48.84, 38.32, 34.67, 30.98, 22.01. HRMS (ESI+): 
calcd for C20H21N3O9 (M + H)
+ 448.1356, found 448.1351. 
 
N-(2-Chloro-5-nitrophenyl)-2-methylquinoline-6-carboxamide  
2-Methylquinoline-6-carboxylic acid (1.50 g, 8.01 mmol) was suspended in anhydrous DCM 
(40 mL) under inert atmosphere. DMF (1.40 µl, 0.018 mmol) and oxalyl chloride (0.74 mL, 8.74 
mmol) were added dropwise and the resulting green solution was allowed to stir at 20 °C for 3 h, 
after which time it was concentrated in vacuo to afford a dry pale green solid. The solid was 
dissolved in pyridine (40.0 mL) and 2-chloro-5-nitroaniline 17 (1.26 g, 7.28 mmol) was added in 
one portion. The resulting dark yellow suspension was allowed to stir for 2 h, then it was poured 
onto water and the yellow precipitate was filtered and washed several times with water, Et2O and 
finally with a minimum amount of DCM to afford the crude product as a yellow amorphous solid 
which was used without further purification (2.20 g, 88%). 1H-NMR (500 MHz, DMSO-d6): δ 
10.59 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.60 (d, J = 2.7 Hz, 1H), 8.44 (d, J = 8.6 Hz, 1H), 8.25 
(dd, J = 8.6, 2.0 Hz, 1H), 8.15 (dd, J = 8.6, 2.7 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.91 (d, J  = 
8.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 2.71 (s, 3H). HRMS (ESI+): Found [M+H]+ 342.0646 
C17H13
35ClN3O3 requires 342.0640. 
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N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-(2-(2-(2-((2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-1-
yl)methyl)quinoline-6-carboxamide 16 (CCT367766) 
2-(2,6-Dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione 2 (29 mg, 0.100 mmol) was 
dissolved in anhydrous THF (1 ml) under argon and then triphenylphosphine (29 mg, 0.110 
mmol) was added and N-(2-chloro-5-(2,3-dihydro-1,4-benzodioxine-6-carbonylamino)phenyl)-2-
((4-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)piperazin-1-yl)methyl)quinoline-6-carboxamide 20 
(72.00 mg, 0.1000 mmol) were added, followed by tert-butyl (NE)-N-tert-
butoxycarbonyliminocarbamate (25 mg, 0.110 mmol). The reaction was stirred at room 
temperature for 2 h. The crude product was purified by Biotage chromatography using a gradient 
of 0-30% MeOH in DCM to afford the product as a pale yellow amorphous solid (27 mg, 27%). 
1H NMR (500 MHz, DMSO-d6) δ 11.13 (s, 1H), 10.34 (s, 1H), 10.28 (s, 1H), 8.67 (d, J = 2.1 Hz, 
1H), 8.50 (d, J = 8.5 Hz, 1H), 8.27 (dd, J = 8.7, 2.0 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.10 (d, J 
= 8.8 Hz, 1H), 7.80 (dd, J = 8.5, 7.3 Hz, 1H), 7.75 (dd, J = 8.8, 2.5 Hz, 1H), 7.72 (d, J = 8.5 Hz, 
1H), 7.57 – 7.52 (m, 4H), 7.45 (d, J = 7.2 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 5.10 (dd, J = 12.8, 
5.4 Hz, 1H), 4.38 – 4.28 (m, 6H), 3.87 – 3.76 (m, 4H), 3.65 (d, J = 5.0 Hz, 2H), 3.54 (s, 4H), 
2.89 (ddd, J = 16.9, 13.8, 5.4 Hz, 1H), 2.69 – 2.32 (m, 12H), 2.08 – 1.99 (m, 1H).13C NMR (126 
MHz, DMSO-d6) δ 172.78, 169.93, 166.79, 165.27, 164.98, 164.65, 155.83, 148.27, 146.58, 
142.97, 138.59, 137.56, 136.97, 134.88, 133.23, 131.37, 129.37, 128.83, 128.42, 127.90, 127.30, 
126.23, 123.55, 121.82, 121.33, 119.99, 119.82, 119.24, 116.93, 116.75, 116.29, 115.39, 79.18, 
70.10, 69.70, 68.90, 68.66, 64.42, 64.03, 57.22, 53.03, 48.75, 30.96, 22.02 (1 signal not 
observed/overlapping signals). HRMS (ESI+): calcd for C49H49
35ClN7O11 (M + H)
+ 947.3173, 
found 947.3173. 
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N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-methylquinoline-
6-carboxamide 18 
2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (1.27 g, 7.06 mmol) was suspended in 
anhydrous DCM (20 mL) under inert atmosphere. DMF (1.23 µl, 0.016 mmol) and oxalyl 
chloride (0.65 mL, 7.70 mmol) were added dropwise and the resulting green solution was 
allowed to stir at 20 °C for 3 h, after which time it was concentrated under vacuum to afford a 
dry pale green solid. The solid was dissolved in pyridine (20 mL) and N-(5-amino-2-
chlorophenyl)-2-methylquinoline-6-carboxamide 24 (2.00 g, 6.42 mmol) was added in one 
portion. The resulting dark yellow suspension was allowed to stir for 2 h, then it was poured onto 
water and the yellow precipitate was filtered and washed several times with water, Et2O and 
finally with a minimum amount of DCM to afford the crude product as a pale yellow amorphous 
solid, which was carried onto the next step without  purification (1.86 g, 61%). 1H-NMR (500 
MHz, DMSO-d6): δ 10.31 (s, 1H), 10.27 (s, 1H), 8.63 (d, J = 1.5 Hz, 1H), 8.43 (d, J = 8.8 Hz, 
1H), 8.25 (dd, J = 8.8, 2.2 Hz, 1H), 8.14 (d, J = 2.2 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.75 (dd, J  
= 8.8, 2.9 Hz, 1H), 7.58-7.49 (m, 4H), 7.00 (d, J = 8.8 Hz, 1H), 4.37-4.26 (m, 4H), 2.71 (s, 3H). 
HRMS (ESI+): Found [M+H]+ 474.1210 C26H21
35ClN3O4 requires 474.1215. 
 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl) -2-(piperazin-1-
ylmethyl)quinoline-6-carboxamide 19 
N-[2-Chloro-5-(2,3-dihydro-1,4-benzodioxine-6-carbonylamino)phenyl)-2-methyl-quinoline-
6-carboxamide 18 (4.00 g, 8.44 mmol) was taken up in anhydrous DMF (20.00 mL) and 
anhydrous 1,4-dioxane (20 mL). Selenium dioxide (1.03 g, 9.28 mmol) was added and the 
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reaction was degassed via 3 x vacuum/nitrogen cycles. The reaction mixture was heated to 50 ºC 
and stirred for 16 h. Then, the reaction was filtered through Celite, eluting with 1:1 DCM/EtOAc 
and concentrated in vacuo. Remaining DMF was removed by azeotrope with EtOAc/heptane to 
afford N-(2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-
formylquinoline-6-carboxamide as a brown solid. The crude material was used directly in the 
next step, assuming 100% yield, without further purification. Sodium cyanoborohydride (2.12 g, 
33.8 mmol) was added to a stirring suspension of N-(2-chloro-5-(2,3-dihydro-1,4-benzodioxine-
6-carbonylamino)phenyl)-2-formyl-quinoline-6-carboxamide (4.12 g, 8.44 mmol)  and 1-Boc-
piperazine (3.15 g, 16.89 mmol) in anhydrous DMF (60 mL) at 0 °C under nitrogen. Then, acetic 
acid (0.53 mL, 9.29 mmol) was added. The reaction mixture was allowed to warm to room 
temperature and stirred overnight. A bleach bubbler was used to vent the reaction. The reaction 
was quenched by slow addition of an aqueous solution of 1M NaOH (50 ml) and the reaction 
mixture concentrated in vacuo, using heptane for azeotropic removal of DMF. The resulting 
residue was taken up in a small amount of MeOH and poured into a large volume of water (300-
400 ml). The precipitate formed was collected by filtration, washed with water, then Et2O and 
dried under vacuum overnight to afford the crude tert-butyl 4-((6-((2-chloro-5-(2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)carbamoyl)quinolin-2-
yl)methyl)piperazine-1-carboxylate as a pale brown solid (4.57 g). This material was used 
directly in the next reaction without further purification. 
To a solution of tert-butyl 4-((6-((2-chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamido)phenyl)carbamoyl)quinolin-2-yl)methyl)piperazine-1-carboxylate (4.57 g, 6.94 
mmol) in anhydrous MeOH (60 mL)  at 0°C under argon was added 4M HCl in dioxane (26.1 
mL, 104.4 mmol). Upon addition of the acid the reaction mixture became darker red/brown in 
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color. The reaction was allowed to warm to room temperature and stirred overnight. Then, the 
solvents were removed in vacuo. The resulting residue was suspended in a small amount of 
MeOH. The suspension was poured into a large volume of water (with stirring) and the 
precipitate formed was collected by filtration, washed well with water, then Et2O and dried under 
vacuum to afford the crude product as a brown solid (3.42 g). Purification by Biotage column 
chromatography using a gradient of 0-10% MeOH in DCM + 1% 7N NH3 in MeOH afforded the 
title compound as a dark yellow amorphous solid (1.53 g, 32% over 3 steps). 1H NMR (500 
MHz, DMSO-d6) δ 10.32 (s, 1H), 10.27 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 8.4 Hz, 
1H), 8.26 (dd, J = 8.8, 2.0 Hz, 1H), 8.15 (d, J = 2.5 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.76 – 7.71 
(m, 2H), 7.58 – 7.47 (m, 3H), 7.00 (d, J = 8.4 Hz, 1H), 4.40 – 4.23 (m, 4H), 3.76 (s, 2H), 2.74 (t, 
J = 4.8 Hz, 4H), 2.47 – 2.42 (br m, 4H) (1 proton missing). 13C NMR (126 MHz, DMSO-d6) δ 
165.00, 164.64, 161.79, 148.29, 146.57, 142.97, 138.58, 137.45, 134.89, 131.32, 129.36, 128.81, 
128.39, 127.85, 127.31, 126.21, 123.54, 121.85, 121.32, 119.81, 119.23, 116.92, 116.74, 65.11, 
64.42, 64.03, 54.26, 45.54. HRMS (ESI+): calcd for C30H29
35ClN5O4 (M + H)
+ 558.1903, found 
558.1885. 
 
2-(2-(2-(4-((6-((2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-
carboxamido)phenyl)carbamoyl)quinolin-2-yl)methyl)piperazin-1-yl)ethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate 20 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl) -2-(piperazin-1-
ylmethyl)quinoline-6-carboxamide 19 (500 mg, 0.90 mmol) was dissolved in anhydrous DMF (8 
ml) under nitrogen at room temperature. K2CO3 (372 mg, 2.69 mmol) was added, followed by a 
solution of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (573 mg, 1.88 mmol) 
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in anhydrous DMF (2 mL) and the reaction stirred at room temperature overnight. Further 2-(2-
(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (286 mg, 0.94 mmol) in anhydrous 
DMF (1 mL) was added and the reaction stirred overnight. The reaction mixture was poured into 
water and the aqueous layer extracted three times with 10% MeOH in DCM. The combined 
organic layer was washed with brine, dried (Na2SO4) and concentrated in vacuo. EtOAc/heptane 
was added to remove remaining traces of DMF by azeotrope. The crude oil was purified by 
Biotage chromatography using a gradient of 0-10% MeOH in DCM + 1% 7N NH3 in MeOH to 
afford the title compound as a yellow amorphous solid (297 mg, 48%). 1H NMR (500 MHz, 
CDCl3) δ 8.63 (s, 1H), 8.59 (d, J = 2.5 Hz, 1H), 8.42 (d, J = 1.9 Hz, 1H), 8.28 (d, J = 8.5 Hz, 
1H), 8.21 (d, J = 8.8 Hz, 1H), 8.17 (dd, J = 8.8, 2.0 Hz, 1H), 7.98 (dd, J = 8.8, 2.5 Hz, 1H), 7.95 
(s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.47 (s, 1H), 7.45 (d, J = 6.6 Hz, 1H), 7.40 (dd, J = 8.4, 2.2 Hz, 
1H), 6.97 (d, J = 8.4 Hz, 1H), 4.42 – 4.43 (m, 4H), 3.90 (s, 2H), 3.78 – 3.71 (m, 2H), 3.71 – 3.66 
(m, 2H), 3.66 – 3.59 (m, 6H), 2.74 – 2.56 (m, 10H). 13C NMR (126 MHz, CDCl3) δ 165.20, 
165.02, 162.36, 149.26, 147.08, 143.70, 138.10, 137.49, 134.77, 131.89, 130.26, 129.63, 127.91, 
127.88, 126.89, 122.42, 120.64, 117.96, 117.57, 117.05, 116.93, 112.63, 72.76, 70.49, 70.44, 
68.81, 65.16, 64.70, 64.32, 61.83, 57.90, 53.69, 53.39. (1 signal not observed/overlapping 
signals). HRMS (ESI+): calcd for C36H41
35ClN5O7 (M + H)
+690.2689, found 690.2692. 
 
N-(4-Chloro-3-nitrophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide  
2,3-Dihydro-1,4-benzodioxine-5-carboxylic acid (1.73 g, 9.61 mmol) was suspended in 
anhydrous DCM (45 mL) and 3 drops of anhydrous DMF were added. Oxalyl chloride (0.81 mL, 
9.61 mmol) was added dropwise (effervescence observed) and the reaction stirred at room 
temperature under nitrogen for 2 h. After this time the effervescence had ceased and the reaction 
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mixture had become fully dissolved. Then, the solvents were removed in vacuo. Anhydrous 
DCM (10 mL) was added and the reaction concentrated again. The residue was taken up in 
anhydrous DCM (5 mL, then 1 mL to rinse flask) and added slowly to a solution of 4-chloro-3-
nitro-aniline 23 (1.11 g, 6.41 mmol) and pyridine (1.55 mL, 19.22 mmol) in anhydrous DCM (45 
mL). The reaction was stirred at room temperature under nitrogen for 48 h. The solvent was 
removed in vacuo and the resulting residue partitioned between saturated aqueous NaHCO3 
solution and 10% MeOH in DCM (30 mL). The aqueous layer was extracted with two further 
portions of 10% MeOH in DCM (30 ml), the combined organic layer was washed with water, 
brine, dried (Na2SO4) and concentrated in vacuo, then dried in vacuo to afford the crude product 
as a pale brown solid (2.24 g). 
However, this material was contaminated with 2,3-dihydro-1,4-benzodioxine-5-carboxylic 
acid, therefore the solid was suspended in a small volume of MeOH and diluted with saturated 
aqueous NaHCO3 solution. The suspension was vigorously stirred for 1 h, after which time the 
precipitate was collected by filtration. The precipitate was washed with copious amounts of 
water, followed by a small portion of Et2O, then dried under vacuum to afford the product as a 
beige amorphous solid (1.82 g, 84%). 1H NMR (500 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.55 (d, J 
= 2.5 Hz, 1H), 7.95 (dd, J = 8.8, 2.5 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.15 (dd, J = 7.6, 1.6 Hz, 
1H), 7.05 (dd, J = 8.1, 1.6 Hz, 1H), 6.94 (t, J = 7.8 Hz, 1H), 4.39 – 4.26 (m, 4H). 13C NMR (126 
MHz, DMSO-d6) δ 164.71, 147.29, 143.70, 141.31, 138.82, 132.01, 124.79, 124.51, 121.25, 
120.84, 119.59, 118.73, 115.87, 64.52, 63.77. HRMS (ESI+): calcd for C15H12
35ClN2O5 (M + H)
+ 
335.0429, found 335.0413. 
N-(3-Amino-4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide 
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N-(4-chloro-3-nitro-phenyl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide (1.50 g, 4.48 mmol) 
 was suspended in a mixture of  DCM (18 mL)  and EtOH (9 mL). 10% Pd/C (200 mg) was 
added and the reaction mixture stirred for 3 days under 1 atm H2. The reaction mixture was 
filtered through Celite, eluting with 10% MeOH in DCM. The filtrate was concentrated in vacuo 
and dried under high vacuum to afford the crude product as a pale brown solid (1.13 g, 93% 
purity, 77%) which was used directly in the next reaction. A portion of this material (320 mg) 
was purified by Biotage chromatography using a gradient of 0 to 5% EtOAc in DCM to afford 
the title compound as a pale yellow amorphous solid (198 mg, 52% based on starting material). 
1H NMR (500 MHz, DMSO-d6) δ 9.93 (s, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.10 (d, J = 8.8 Hz, 2H), 
6.99 (dd, J = 8.0, 1.5 Hz, 1H), 6.91 (t, J = 7.8 Hz, 1H), 6.81 (dd, J = 8.6, 2.3 Hz, 1H), 5.37 (s, 
2H), 4.39 – 4.32 (m, 2H), 4.31 – 4.27 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.77, 
144.72, 143.63, 141.13, 138.48, 128.82, 125.80, 121.21, 120.70, 118.98, 111.77, 108.78, 106.29, 
64.43, 63.74. HRMS (ESI+): calcd for C15H14
35ClN2O3 (M + H)
+ 305.0687, found 305.0688. 
 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamido)phenyl)-2-methylquinoline-
6-carboxamide 
2-Methylquinoline-6-carboxylic acid (685 mg, 3.66 mmol) was dissolved in anhydrous DCM 
(24 mL) at room temperature under inert atmosphere and 1 drop anhydrous DMF added. Then, 
oxalyl chloride (0.31 mL, 3.66 mmol) was added dropwise (effervescence observed) and the 
reaction stirred at room temperature for 2 h, over which time effervescence ceased and the 
solution became dark green. The solvent was removed in vacuo. The resulting residue was re-
dissolved in anhydrous DCM (2 ml) and concentrated in vacuo (x 2). The solid was taken up in 
anhydrous DCM (1 ml, then 1 ml to rinse flask) and slowly added to a stirring solution of N-(3-
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amino-4-chloro-phenyl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide (800.00 mg, 2.44 mmol)  
in anhydrous pyridine (18 mL) at room temperature under inert atmosphere. The reaction was 
stirred overnight. A precipitate formed which was isolated by filtration, washed with water (x 2), 
ether and then dried under vacuum to afford the product as a beige amorphous solid (672 mg, 
58%). 1H NMR (500 MHz, DMSO-d6) δ 10.33 (s, 1H), 10.32 (s, 1H), 8.63 (d, J = 1.8 Hz, 1H), 
8.42 (d, J = 8.5 Hz, 1H), 8.25 (dd, J = 8.8, 2.0 Hz, 1H), 8.07 (d, J = 2.3 Hz, 1H), 8.04 (d, J = 8.8 
Hz, 1H), 7.68 (dd, J = 8.8, 2.4 Hz, 1H), 7.54 (dd, J = 8.6, 2.8 Hz, 2H), 7.15 (dd, J = 7.6, 1.5 Hz, 
1H), 7.02 (dd, J = 8.0, 1.6 Hz, 1H), 6.93 (t, J = 7.8 Hz, 1H), 4.37 (dd, J = 5.1, 2.4 Hz, 2H), 4.31 
(dd, J = 5.0, 2.7 Hz, 2H), 2.71 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.07, 164.24, 
160.97, 148.57, 143.67, 141.20, 138.27, 137.25, 135.12, 130.87, 129.53, 128.46, 128.44, 127.85, 
125.51, 125.39, 123.79, 123.07, 121.19, 120.76, 119.31, 119.19, 118.67, 64.47, 63.77, 25.05. 
HRMS (ESI+): calcd for C26H21
35ClN3O4 (M + H)
+ 474.1215, found 474.1192. 
 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamido)phenyl)-2-(piperazin-1-
ylmethyl)quinoline-6-carboxamide  
N-(2-Chloro-5-(2,3-dihydro-1,4-benzodioxine-5-carbonylamino)phenyl)-2-methyl-quinoline-
6-carboxamide (500 mg, 1.06 mmol) was taken up in anhydrous DMF (5 mL) and anhydrous 
1,4-dioxane (5 mL). Selenium dioxide (128 mg, 1.16 mmol) was added, the reaction was 
degassed via 3 x vacuum/nitrogen cycles and stirred at 50°C for 5 h. The reaction mixture was 
filtered through Celite (eluting with 1:1 DCM/EtOAc), then concentrated in vacuo, using 
EtOAc/heptane to remove traces of DMF. This material was used directly in the next reaction 
without further purification, assuming 100% yield. 
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N-[2-Chloro-5-(2,3-dihydro-1,4-benzodioxine-5-carbonylamino)phenyl]-2-formyl-quinoline-6-
carboxamide (0.51 g, 1.06 mmol)  and 1-Boc-piperazine (392 mg, 2.11 mmol) were dissolved in 
anhydrous DMF (10 mL) at 0 °C  under nitrogen. Then, sodium cyanoborohydride (265 mg, 4.22 
mmol) was added in one portion, followed by acetic acid (0.07 mL, 1.16 mmol). A bleach 
bubbler was used to vent the reaction. The reaction was allowed to warm to room temperature 
and stirred overnight. The reaction was quenched by addition of 1M NaOH (aq.) and then 
concentrated in vacuo. The resulting residue was suspended in MeOH and diluted with water to 
afford a brown precipitate. The precipitate was collected by filtration and washed well with 
water, followed by Et2O and dried under vacuum to afford the product as a pale brown solid (520 
mg). This material was used directly in the next reaction without further purification. 
tert-Butyl 4-((6-((2-chloro-5-(2,3-dihydro-1,4-benzodioxine-5 
carbonylamino)phenyl)carbamoyl)-2-quinolyl)methyl)piperazine-1-carboxylate (508 mg, 0.770 
mmol) was dissolved in anhydrous MeOH (7 mL) at 0 °C under inert atmosphere. Then, 4M HCl 
in dioxane (2.90 mL, 11.61 mmol) was added and the reaction warmed to room temperature. 
After 1.5 h, further 4M HCl in dioxane (2.90 mL, 11.61 mmol) was added and the reaction 
stirred overnight. Then, the reaction mixture was concentrated in vacuo. The resulting residue 
was taken up in 1:1 MeOH/DCM and subjected to Isolute Flash SCX-II chromatography to 
afford the free salt, eluting first with MeOH followed by 10% 7N NH3 in MeOH. This material 
was further purified by Biotage chromatography using a gradient of 0-10% MeOH in DCM + 1% 
7N NH3 in MeOH to afford the title compound as a pale brown amorphous solid (253 mg, 43% 
over 3 steps). 1H NMR (500 MHz, DMSO-d6) δ 10.35 (s, 1H), 10.32 (s, 1H), 8.71 – 8.54 (m, 
1H), 8.49 (d, J = 8.5 Hz, 1H), 8.26 (dd, J = 8.8, 1.8 Hz, 1H), 8.09 (app. d, J = 8.6 Hz, 2H), 7.74 
(d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.8, 2.3 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.14 (dd, J = 7.6, 1.3 
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Hz, 1H), 7.02 (dd, J = 8.0, 1.5 Hz, 1H), 6.93 (t, J = 7.8 Hz, 1H), 4.42 – 4.34 (m, 2H), 4.33 – 4.29 
(m, 2H), 3.77 (s, 2H), 2.76 (t, J = 4.5 Hz, 4H), 2.42 (br s, 4H) (1 proton missing). 13C NMR (126 
MHz, DMSO-d6) δ 165.00, 164.24, 161.72, 148.30, 143.67, 141.20, 138.27, 137.48, 135.08, 
131.28, 129.54, 128.81, 128.44, 127.88, 126.22, 125.50, 123.78, 121.86, 121.19, 120.76, 119.32, 
119.19, 118.70, 65.02, 64.47, 63.77, 53.94, 48.60, 45.37 (1 missing/overlapping signal). HRMS 
(ESI+): calcd for C30H29
35ClN5O4 (M + H)
+ 558.1903, found 558.1890. 
 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamido)phenyl)-2-((4-(2-(2-(2-
hydroxyethoxy)ethoxy)ethyl)piperazin-1-yl)methyl)quinoline-6-carboxamide 
N-(2-Chloro-5-(2,3-dihydro-1,4-benzodioxine-5-carbonylamino)phenyl)-2-(piperazin-1-
ylmethyl)quinoline-6-carboxamide (248 mg, 0.440 mmol) was dissolved in anhydrous DMF (3 
ml) at room temperature under inert atmosphere and K2CO3 (371 mg, 2.69 mmol) was added. 
Then, a solution of 2-(2-(2 hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (573 mg, 1.88 
mmol) in anhydrous DMF (1 mL) was added and reaction stirred overnight. The reaction was 
diluted with water and the aqueous layer extracted (3 x 10% MeOH in DCM). The combined 
organic layer was washed with brine and dried (Na2SO4). Purification by Biotage 
chromatography using a gradient of 0-10% MeOH in DCM + 1% 7N NH3 in MeOH gave the 
title compound as a pale yellow amorphous solid (108 mg, 35%). 1H NMR (500 MHz, CDCl3) δ 
9.59 (s, 1H), 8.63 (s, 1H), 8.54 (d, J = 2.5 Hz, 1H), 8.42 (d, J = 1.6 Hz, 1H), 8.27 (d, J = 8.5 Hz, 
1H), 8.21 (d, J = 8.8 Hz, 1H), 8.17 (dd, J = 8.8, 1.9 Hz, 1H), 8.00 (dd, J = 8.8, 2.5 Hz, 1H), 7.81 
(dd, J = 7.8, 1.7 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.8 Hz, 1H), 7.07 (dd, J = 8.0, 1.7 
Hz, 1H), 6.99 (t, J = 7.9 Hz, 1H), 4.56 (dd, J = 5.0, 3.1 Hz, 2H), 4.38 (dd, J = 5.0, 3.1 Hz, 2H), 
3.89 (s, 2H), 3.77 – 3.71 (m, 2H), 3.70 – 3.58 (m, 8H), 2.73 – 2.53 (m, 10H) (1 proton missing). 
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13C NMR (126 MHz, CDCl3) δ 164.98, 163.11, 162.34, 149.27, 143.81, 141.99, 138.12, 137.44, 
134.75, 131.96, 130.31, 129.55, 127.80, 126.89, 124.52, 122.41, 122.16, 121.76, 121.56, 118.01, 
117.66, 113.13, 72.74, 70.48, 70.44, 68.82, 65.46, 65.14, 63.75, 61.82, 57.87, 53.67, 53.36 (1 
overlapping/missing signal). HRMS (ESI+): calcd for C36H41
35ClN5O7 (M + H)
+ 690.2689, found 
690.2696. 
 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamido)phenyl)-2-((4-(2-(2-(2-((2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-1-
yl)methyl)quinoline-6-carboxamide 21 
2-(2,6-Dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione (19.87 mg, 0.0700 mmol) was 
dissolved in anhydrous THF ( 0.72 mL) under inert atmosphere, then triphenylphosphine (19.95 
mg, 0.0800 mmol) and tert-butyl (NE)-N-tert-butoxycarbonyliminocarbamate (17.51 mg, 0.0800 
mmol) were added, followed by N-(2-chloro-5-(2,3-dihydro-1,4-benzodioxine-5-
carbonylamino)phenyl)-2-((4-(2-(2-(2-hydroxyethoxy)ethoxy]ethyl)piperazin-1-
yl)methyl)quinoline-6-carboxamide (50.00 mg, 0.070 mmol). The reaction was stirred at room 
temperature for 2 h. The reaction mixture was pre-absorbed onto silica and purified by Biotage 
chromatography using a gradient of 0-30% MeOH in DCM to afford the product as a pale yellow 
amorphous solid (28 mg, 41%). 1H NMR (500 MHz, DMSO-d6) δ 11.12 (s, 1H), 10.35 (s, 1H), 
10.32 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 8.6 Hz, 1H), 8.26 (dd, J = 8.8, 2.0 Hz, 1H), 
8.13 – 8.06 (m, 2H), 7.79 (dd, J = 8.6, 7.2 Hz, 1H), 7.75 – 7.65 (m, 2H), 7.53 (t, J = 8.4 Hz, 2H), 
7.44 (d, J = 7.2 Hz, 1H), 7.14 (dd, J = 7.6, 1.7 Hz, 1H), 7.02 (dd, J = 8.0, 1.7 Hz, 1H), 6.93 (t, J 
= 7.8 Hz, 1H), 5.09 (dd, J = 12.8, 5.5 Hz, 1H), 4.42 – 4.26 (m, 6H), 3.85 – 3.73 (m, 4H), 3.64 
(dd, J = 5.9, 3.7 Hz, 2H), 3.54 – 3.46 (dt, J = 11.8, 5.7 Hz, 4H), 2.88 (ddd, J = 16.9, 13.8, 5.4 Hz, 
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1H), 2.65 – 2.23 (m, 12H), 2.09 – 1.96 (m, 1H). 13C NMR (126 MHz, DMSO-d6) δ 172.76, 
169.90, 166.79, 165.24, 164.98, 164.23, 161.71, 155.84, 148.28, 143.66, 141.19, 138.26, 137.51, 
136.95, 135.07, 133.23, 131.27, 129.53, 128.81, 128.43, 127.87, 126.21, 125.50, 123.76, 121.79, 
121.18, 120.76, 120.01, 119.30, 119.18, 118.68, 116.31, 115.37, 70.12, 69.72, 68.90, 68.67, 
68.21, 64.46, 64.35, 63.76, 57.22, 54.91, 53.13, 53.01, 48.74, 40.02, 30.95, 22.01. HRMS (ESI+): 
calcd for C49H49
35ClN7O11 (M + H)
+ 946.3173, found 946.3183. 
 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-ethylpiperazin-
1-yl)methyl)quinoline-6-carboxamide 22 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-methylquinoline-
6-carboxamide 18 (1.00 g, 2.11 mmol) was taken up in anhydrous DMF (10 mL) and anhydrous 
1,4-dioxane (10 mL). Selenium dioxide (280 mg, 2.53 mmol) was added, the reaction was 
degassed via 3 x vacuum/nitrogen cycles and stirred at 50 ºC under nitrogen for 3.5 h. Further 
selenium dioxide (47 mg, 0.42 mmol) was added and the reaction stirred at 50 ºC for an 
additional 2 h. The reaction mixture was cooled, filtered through Celite (eluting with 
DCM/EtOAc) and concentrated in vacuo, using EtOAc/heptane azeotrope to remove DMF. This 
material was used directly in the next reaction without further purification, assuming 100% yield. 
N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-formylquinoline-
6-carboxamide (1.03 g, 2.11 mmol) was suspended in anhydrous DCM (20 mL) at room 
temperature under nitrogen and 1-ethylpiperazine (0.80 mL, 6.33 mmol) was added. The reaction 
was allowed to stir overnight, then NaBH(OAc)3 (1.34 g, 6.33 mmol) was added and stirred for 3 
h. The reaction mixture was quenched with a saturated aqueous solution of NaHCO3 and the 
aqueous layer extracted with 10% MeOH in DCM (x 3). The combined organic layer was dried 
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(Na2SO4) and concentrated in vacuo. The residue was purified by Biotage chromatography using 
a gradient of 0-10% MeOH in DCM. This material was further purified by Isolute Flash SCX-II 
chromatography, eluting with MeOH, followed by 10% 7N NH3 in MeOH to afford the product 
as an amorphous yellow solid (431 mg, 35%).1H NMR (500 MHz, DMSO-d6) δ 10.32 (s, 1H), 
10.27 (s, 1H), 8.65 (d, J = 1.9 Hz, 1H), 8.50 (d, J = 8.5 Hz, 1H), 8.26 (dd, J = 8.8, 2.0 Hz, 1H), 
8.15 (d, J = 2.5 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.77 – 7.74 (m, 1H), 7.73 (d, J = 8.7 Hz, 1H), 
7.56 – 7.50 (m, 3H), 7.00 (d, J = 8.4 Hz, 1H), 4.34 – 4.26 (m, 4H), 3.80 (s, 2H), 2.60 – 2.25 (m, 
10H), 0.99 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.00, 164.64, 161.70, 
148.28, 146.57, 142.97, 138.58, 137.52, 134.89, 131.35, 129.35, 128.82, 128.39, 127.87, 127.31, 
126.23, 123.53, 121.82, 121.32, 119.80, 119.23, 116.92, 116.74, 64.42, 64.35, 64.03, 52.94, 
52.34, 51.59, 11.92. HRMS (ESI+): calcd for C32H33
35ClN5O4 (M + H)
+, 586.2216; found 
586.2239. 
 
N-(5-Amino-2-chlorophenyl)-2-methylquinoline-6-carboxamide 24 
N-(2-Chloro-5-nitrophenyl)-2-methylquinoline-6-carboxamide was suspended in water (7 mL) 
and EtOH (21 mL). Ammonium chloride (2.41 g, 45.1 mmol) and iron powder (2.52 g, 45.1 
mmol) were added and the resulting suspension was allowed to stir at 90 °C for 1 h. The reaction 
mixture was allowed to cool to room temperature, diluted with MeOH and DCM and filtered 
through a pad of Celite. The resulting filtrate was concentrated under vacuum to afford a light 
brown amorphous solid as crude product, which was used directly in the next step without any 
further purification (2.00 g, 100%). 1H-NMR (500 MHz, DMSO-d6): δ  9.96 (s, 1H), 8.58 (d, J = 
2.2 Hz, 1H), 8.41 (d, J = 8.7 Hz, 1H), 8.21 (dd, J = 8.7, 2.2 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 
7.53 (d, J  = 7.6 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.50 (dd, J = 8.7, 2.2 
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Hz, 1H), 5.41 (bs, 2H), 2.70 (s, 3H). HRMS (ESI+): Found [M+H]+ 312.0902 C17H15
35ClN3O 
requires 312.0898. 
 
1-(6-((2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethyl-2-((1E,3E)-5-((E)-1,3,3-
trimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium-5-sulfonate 
In the absence of light, N-(2-(2-aminoethoxy)ethyl)-2-(2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-
isoindolin-4-yl)oxy-acetamide hydrochloride 4 ( 0.60 mg, 0.0013 mmol) was added to a solution 
of sodium (2E)-2-((2E,4E)-5-(1-(6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxo-hexyl)-3,3-dimethyl-5-
sulfonato-indol-1-ium-2-yl)penta-2,4-dienylidene)-1,3,3-trimethyl-indoline-5-sulfonate (1.00 
mg, 0.0013 mmol) dissolved in 20 µL of triethylamine and 300 µL of DMF and the deep blue 
solution was left to stand for for 16 hours. The crude product was then purified by semi-
preparative HPLC to give the desired product. LCMS (ESI+) RT = 2.59 min, 77%, M+H+ 1043. 
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ABBREVIATIONS 
SAR, structure activity relationships; CETSA, cellular thermal shift assay; ABPP, activity-
based protein profiling; PROTAC, proteolysis targeting chimera; SNIPER, specific and non-
genetic IAP-dependent protein eraser; PDP, protein degradation probe; SPR, surface plasmon 
resonance spectroscopy; SEM, standard error of the mean; HPLC, high-performance liquid 
chromatography; KS, kinetic solubility; tPSA, topological polar surface area; DMSO, dimethyl 
sulfoxide; HSF1, heat shock transcription factor 1; BRD4, bromodomain-containing protein 4; 
VHL, Von Hippel-Lindau disease tumor suppressor; IAP, inhibitors of apoptosis proteins; 
CRBN, protein cereblon; PPI, protein-protein interaction; TBAF, tetra-n-butylammonium 
fluoride; HBD, hydrogen bond donor; TMT, tandem mass tagging; MS2, MS/MS mass 
spectrometry; DTBAD, di-tertbutylazocarboxylate; THF, tetrahydrofuran; DCM, 
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dichloromethane; RT, room temperature; HATU, 1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; DIPEA, diisopropylethylamine; DMF, 
dimethylformamide; DBU, 1,8-diazabicyclo(5.4.0)undec-7-ene; SF, significant figures. 
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Figure 1. (Top) Pirin (5JCT)/CRBN (5CI1)/PDP ternary complex design model. The PDP can either stabilize a 
PPI or simply bring the proteins in close proximity, depending on the role of the linker. (Bottom Left) 
Cartoon representation of the chemical probe 1 (yellow) bound to recombinant pirin (5JCT). The cloud 
represents the shape of the binding pocket with key residues shown in black and the metal in orange. 
Red=oxygen, blue=nitrogen. Hydrogens and solvent are omitted for clarity except the water coordinated to 
the metal, shown as a red sphere. Both representations were generated using the PyMOL Molecular Graphics 
System, Version 1.8 Schrödinger, LLC. (Bottom Right) Key residues in the binding site and the clear solvent 
exposed vector for the chemical probe 1 binding to pirin are shown, adapted from an analysis using MOE 
2014.09. The ethyl pyrrolidine solubilizing group of chemical probe 1 was not resolved in the crystal 
structure and therefore is not drawn in the analysis.  
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Table 1. Physicochemical Properties and Affinities for Recombinant Protein Targets of the Three Generations 
of PDPs  
SF=significant figure. All data was reprocessed using GraphPad Prism 7.01. See figures S8-S16. 
SEM=standard error of the mean. aHBD=hydrogen bond donor count. bALogP was calculated using Biovia 
Pipeline Pilot Version 9.5, 2 SF. cLogD7.4 measured using a HPLC-based method, n=1, 2 SF. dtPSA was 
calculated using ChemDraw (16.0.1.4) based on the O- and N-count, 3 SF. eKS=kinetic solubility in pH7.4 
phosphate buffer at room temperature, n=1, 1 SF. fKD values are reported to 2 SF and are calculated by 
equilibrium analysis using a one site specific binding model from SPR sensorgrams at equilibrium where 
possible, pKD=-log (KD (M) x 10-9) and represents the geometric mean of n=3 independent biological 
repeats. gIC50 values are reported to 2 SF and are calculated from an FP-assay dose-response curve to 
displace a thalidomide derived fluorescent probe using a log[Inhibitor] vs. response – Variable slope (four 
parameters) model, pIC50=-log (IC50 (M) x 10-9) and represents the geometric mean of n=3 independent 
biological repeats, also see reference 31. hKi values are calculated from the geometric mean CRBN-DDB1 
complex IC50 and the FP-probe KD using methods described in reference 32.  
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Reagents and conditions: (a) i) PPh3, tButyl 2-hydroxyacetate, DTBAD, THF, 0 ºC→RT, 16 h, 75%; ii) 
HCO2H, DCM, 40 ºC, 16 h, 54%; iii) HATU, DIPEA, DMF, tButyl (2-(2-aminoethoxy)ethyl)carbamate, RT, 16 
h, 81%; iv) 4 M HCl in dioxane, 0.5 h, 100%; (b) i) ethyl 4-bromobutanoate, K2CO3, DMF, RT, 16 h, 37%; 
(c) Herrmann’s palladacycle,29 tBu3PHBF4, MoCO6, DBU, 2-(trimethylsilyl)ethan-1-ol, 130 oC, 62% (d) i) 
TBAF, THF, RT, 16 h; (e) i) HATU, DIPEA, DMF, RT, 38% (over 2 steps); ii) LiOH.H2O, MeOH/THF/H2O, RT, 
48 h, 18% (f) HATU, DIPEA, DMF, 74%. For the synthesis of hydroxythalidomide 2 see reference 28.  
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Reagents and conditions: (a) i) X=F 12, 2-methylquinoline carboxylic acid, oxalyl chloride, DMF, DCM; RT, 3 
h; then pyridine, 18 h Quant; ii) Fe(0), NH4Cl, EtOH/H2O, 90 ºC, 1 h, Quant; (b) 2,3-dihydrobenzo-
[b][1,4]-dioxine-6-carboxylic acid, oxalyl chloride, DMF, DCM, RT, 3 h; then pyridine RT, 2 h, 85%; (c) i) 
SeO2, 1,4-dioxane/DMF, reflux, 1 h; ii) N-Boc-piperazine, DCM, RT, 12 h then NaBH(OAc)3, DCM, RT, 2 h, 
94% (over 2 steps); iii) TFA, DCM, RT, 2 h, 69% (d) i) 2, PPh3, tButyl 2-hydroxyacetate, DTBAD, THF, 0 
ºC→RT, 16 h, 75%; ii) HCO2H, DCM, 40 ºC, 16 h, 54%; iii) HATU, DIPEA, DMF, tButyl 3-(2-
aminoethoxy)propanoate, RT, 16 h, 72%; iv) HCO2H, DCM, 40 ºC, 6 h, 93% (e) HATU, DIPEA, DMF, RT, 16 
h, 52%; (f) i) X=Cl 17, 2-methylquinoline carboxylic acid, oxalyl chloride, DMF, DCM, RT, 3 h; then pyridine 
2 h, 88%; ii) Fe(0), NH4Cl, EtOH/H2O, 90 ºC, 1 h, Quant; (g) i) 2,3-dihydrobenzo-[b][1,4]-dioxine-6-
carboxylic acid, oxalyl chloride, DMF, DCM, RT, 3 h; then pyridine 2 h, 61%; (h) i) SeO2, DMF, 1,4-dioxane, 
50 ºC, 16 h; ii) N-Boc-piperazine, NaBH3CN, AcOH, DMF, 0 ºC→RT, 16 h iii) 4M HCl in dioxane, MeOH 0 
ºC→RT, 16 h, 32% over 3 steps; (i) 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate, 
K2CO3, DMF, RT, 16 h, 48%; j) PPh3, DTBAD, THF, RT, 2 h, 27%; (k) i) 23, 2,3-dihydro-1,4-benzodioxine-
5-carboxylic acid, oxalyl chloride, DMF, DCM, RT, 2 h; then pyridine 48 h, 84%; ii) Pd/C, EtOH/DCM, H2 (1 
atm), 77%; iii) 2-methylquinoline carboxylic acid, oxalyl chloride, DMF, DCM; RT, 2 h; then pyridine 16 h, 
58%; then same procedure as from 18, 6% yield over 5 steps. (l) SeO2, 1,4-dioxane/DMF, 50 ºC, 5.5 h; ii) 
N-ethylpiperazine, DCM, RT, 20 h; then NaBH(OAc)3, DCM, RT, 2 h, 35% (over 2 steps).  
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Figure 2. (A) Representative SPR sensorgram of the third generation PDP 16 and recombinant pirin. (B) 
Representative binding curve of PDP 16 in the CRBN-DDB1 FP-assay.  
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Figure 3. A: Immunoblot of SK-OV-3 human ovarian cancer cells demonstrating the depletion of pirin protein 
using the third generation PDP 16 and the time-dependent hook-effect. B: Immunoblot demonstrating the 
concentration-dependent depletion of pirin protein after 2 h exposure in SK-OV-3 cells. C: Capillary 
electrophoresis and immunoassay were used to quantify the pirin protein expression after 2 h exposure with 
PDP 16, all values are normalized to vinculin loading control and relative to the measured basal pirin protein 
expression, all bars represent the arithmetic mean of n=3 independent biological repeats, error bars are 
SEM. D: Proteomics analysis of the third generation PDP 16 (50 nM) exposure (4 h) in SK-OV-3 cells 
compared to vehicle control, using a tandem mass tagging (TMT) MS2 protocol on the cell lysate, 8547 
quantifiable proteins were identified, each blue dot represents a single quantifiable protein, pirin is marked 
in red (adjusted p value=1.4 x 10-4), p values were calculated using a linear modelling based t-test and 
corrected for multiple comparisons using the Benjamini-Hochberg method to give the p(adj) values shown, 
dotted lines represent 2-fold depletion of the protein and a p(adj)=0.05.  
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Figure 4. Intracellular competition studies with PDP 16 and the chemical probes. SK-OV-3 cells were pre-
treated with increasing concentrations of chemical probe for 4 h before exposing to PDP 16 for 2 h at the 
concentrations shown. Cells were then lysed and protein expression analyzed using immunoblot. For clarity, 
gel images have been cropped where appropriate.  
 
143x107mm (150 x 150 DPI)  
 
 
Page 68 of 68
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
